1
|
Guo Q, AlKendi A, Jiang X, Mittone A, Wang L, Larsson E, Bravin A, Renström E, Fang X, Zhang E. Reduced volume of diabetic pancreatic islets in rodents detected by synchrotron X-ray phase-contrast microtomography and deep learning network. Heliyon 2023; 9:e13081. [PMID: 36718155 PMCID: PMC9883183 DOI: 10.1016/j.heliyon.2023.e13081] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/15/2022] [Revised: 01/09/2023] [Accepted: 01/16/2023] [Indexed: 01/20/2023] Open
Abstract
The pancreatic islet is a highly structured micro-organ that produces insulin in response to rising blood glucose. Here we develop a label-free and automatic imaging approach to visualize the islets in situ in diabetic rodents by the synchrotron radiation X-ray phase-contrast microtomography (SRμCT) at the ID17 station of the European Synchrotron Radiation Facility. The large-size images (3.2 mm × 15.97 mm) were acquired in the pancreas in STZ-treated mice and diabetic GK rats. Each pancreas was dissected by 3000 reconstructed images. The image datasets were further analysed by a self-developed deep learning method, AA-Net. All islets in the pancreas were segmented and visualized by the three-dimension (3D) reconstruction. After quantifying the volumes of the islets, we found that the number of larger islets (=>1500 μm3) was reduced by 2-fold (wt 1004 ± 94 vs GK 419 ± 122, P < 0.001) in chronically developed diabetic GK rat, while in STZ-treated diabetic mouse the large islets were decreased by half (189 ± 33 vs 90 ± 29, P < 0.001) compared to the untreated mice. Our study provides a label-free tool for detecting and quantifying pancreatic islets in situ. It implies the possibility of monitoring the state of pancreatic islets in vivo diabetes without labelling.
Collapse
Affiliation(s)
- Qingqing Guo
- School of Computer Science and Technology, Anhui University, Hefei, China
- Islet Pathophysiology, Department of Clinical Science, Lund University Diabetes Centre, Malmö, Sweden
| | - Abdulla AlKendi
- Islet Pathophysiology, Department of Clinical Science, Lund University Diabetes Centre, Malmö, Sweden
| | - Xiaoping Jiang
- Islet Pathophysiology, Department of Clinical Science, Lund University Diabetes Centre, Malmö, Sweden
- School of Physical Science and Technology, Southwest University, Chongqing, China
| | - Alberto Mittone
- Advanced Photon Source, Argonne National Laboratory, Lemont, IL, United States
- Biomedical Beamline ID17, European Synchrotron Radiation Facility, Grenoble Cedex, France
| | - Linbo Wang
- School of Computer Science and Technology, Anhui University, Hefei, China
| | - Emanuel Larsson
- Division of Solid Mechanics & LUNARC, Department of Construction Sciences, Lund University, Lund, Sweden
| | - Alberto Bravin
- Biomedical Beamline ID17, European Synchrotron Radiation Facility, Grenoble Cedex, France
- Department of Physics, University Milano Bicocca, Milan, Italy
- Department of Physics, Università della Calabria, Rende, Italy
| | - Erik Renström
- Islet Pathophysiology, Department of Clinical Science, Lund University Diabetes Centre, Malmö, Sweden
| | - Xianyong Fang
- School of Computer Science and Technology, Anhui University, Hefei, China
- Corresponding author.
| | - Enming Zhang
- Islet Pathophysiology, Department of Clinical Science, Lund University Diabetes Centre, Malmö, Sweden
- NanoLund, Lund University, Box 118, 22100, Lund, Sweden
- Corresponding author. Islet Pathophysiology, Department of Clinical Science, Lund University Diabetes Centre, Malmö, Sweden.
| |
Collapse
|
2
|
Barghouth M, Ye Y, Karagiannopoulos A, Ma Y, Cowan E, Wu R, Eliasson L, Renström E, Luan C, Zhang E. The T-type calcium channel Ca V3.2 regulates insulin secretion in the pancreatic β-cell. Cell Calcium 2022; 108:102669. [PMID: 36347081 DOI: 10.1016/j.ceca.2022.102669] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/23/2022] [Revised: 10/26/2022] [Accepted: 10/28/2022] [Indexed: 11/08/2022]
Abstract
Voltage-gated Ca2+ (CaV) channel dysfunction leads to impaired glucose-stimulated insulin secretion in pancreatic β-cells and contributes to the development of type-2 diabetes (T2D). The role of the low-voltage gated T-type CaV channels in β-cells remains obscure. Here we have measured the global expression of T-type CaV3.2 channels in human islets and found that gene expression of CACNA1H, encoding CaV3.2, is negatively correlated with HbA1c in human donors, and positively correlated with islet insulin gene expression as well as secretion capacity in isolated human islets. Silencing or pharmacological blockade of CaV3.2 attenuates glucose-stimulated cytosolic Ca2+ signaling, membrane potential, and insulin release. Moreover, the endoplasmic reticulum (ER) Ca2+ store depletion is also impaired in CaV3.2-silenced β-cells. The linkage between T-type (CaV3.2) and L-type CaV channels is further identified by the finding that the intracellular Ca2+ signaling conducted by CaV3.2 is highly dependent on the activation of L-type CaV channels. In addition, CACNA1H expression is significantly associated with the islet predominant L-type CACNA1C (CaV1.2) and CACNA1D (CaV1.3) genes in human pancreatic islets. In conclusion, our data suggest the essential functions of the T-type CaV3.2 subunit as a mediator of β-cell Ca2+ signaling and membrane potential needed for insulin secretion, and in connection with L-type CaV channels.
Collapse
Affiliation(s)
- Mohammad Barghouth
- Unit of Islet Pathophysiology, Department of Clinical Sciences Malmö, Lund University Diabetes Centre, Lund University, Malmö, 20502, Sweden
| | - Yingying Ye
- Unit of Islet Pathophysiology, Department of Clinical Sciences Malmö, Lund University Diabetes Centre, Lund University, Malmö, 20502, Sweden.
| | - Alexandros Karagiannopoulos
- Unit of Islet Cell Exocytosis, Department of Clinical Sciences Malmö, Lund University Diabetes Centre, Lund University, Malmö 20502, Sweden
| | - Yunhan Ma
- Unit of Islet Pathophysiology, Department of Clinical Sciences Malmö, Lund University Diabetes Centre, Lund University, Malmö, 20502, Sweden
| | - Elaine Cowan
- Unit of Islet Cell Exocytosis, Department of Clinical Sciences Malmö, Lund University Diabetes Centre, Lund University, Malmö 20502, Sweden
| | - Rui Wu
- Unit of Islet Pathophysiology, Department of Clinical Sciences Malmö, Lund University Diabetes Centre, Lund University, Malmö, 20502, Sweden; NanoLund, Lund University, P.O. Box 118, Lund 22100, Sweden
| | - Lena Eliasson
- Unit of Islet Cell Exocytosis, Department of Clinical Sciences Malmö, Lund University Diabetes Centre, Lund University, Malmö 20502, Sweden
| | - Erik Renström
- Unit of Islet Pathophysiology, Department of Clinical Sciences Malmö, Lund University Diabetes Centre, Lund University, Malmö, 20502, Sweden
| | - Cheng Luan
- Unit of Islet Pathophysiology, Department of Clinical Sciences Malmö, Lund University Diabetes Centre, Lund University, Malmö, 20502, Sweden.
| | - Enming Zhang
- Unit of Islet Pathophysiology, Department of Clinical Sciences Malmö, Lund University Diabetes Centre, Lund University, Malmö, 20502, Sweden; NanoLund, Lund University, P.O. Box 118, Lund 22100, Sweden.
| |
Collapse
|
3
|
Asplund O, Storm P, Chandra V, Hatem G, Ottosson-Laakso E, Mansour-Aly D, Krus U, Ibrahim H, Ahlqvist E, Tuomi T, Renström E, Korsgren O, Wierup N, Ibberson M, Solimena M, Marchetti P, Wollheim C, Artner I, Mulder H, Hansson O, Otonkoski T, Groop L, Prasad RB. Islet Gene View-a tool to facilitate islet research. Life Sci Alliance 2022; 5:e202201376. [PMID: 35948367 PMCID: PMC9366203 DOI: 10.26508/lsa.202201376] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/19/2022] [Revised: 07/18/2022] [Accepted: 07/18/2022] [Indexed: 01/27/2023] Open
Abstract
Characterization of gene expression in pancreatic islets and its alteration in type 2 diabetes (T2D) are vital in understanding islet function and T2D pathogenesis. We leveraged RNA sequencing and genome-wide genotyping in islets from 188 donors to create the Islet Gene View (IGW) platform to make this information easily accessible to the scientific community. Expression data were related to islet phenotypes, diabetes status, other islet-expressed genes, islet hormone-encoding genes and for expression in insulin target tissues. The IGW web application produces output graphs for a particular gene of interest. In IGW, 284 differentially expressed genes (DEGs) were identified in T2D donor islets compared with controls. Forty percent of DEGs showed cell-type enrichment and a large proportion significantly co-expressed with islet hormone-encoding genes; glucagon (<i>GCG</i>, 56%), amylin (<i>IAPP</i>, 52%), insulin (<i>INS</i>, 44%), and somatostatin (<i>SST</i>, 24%). Inhibition of two DEGs, <i>UNC5D</i> and <i>SERPINE2</i>, impaired glucose-stimulated insulin secretion and impacted cell survival in a human β-cell model. The exploratory use of IGW could help designing more comprehensive functional follow-up studies and serve to identify therapeutic targets in T2D.
Collapse
Affiliation(s)
- Olof Asplund
- Department of Clinical Sciences, Clinical Research Centre, Lund University, Malmö, Sweden
- Lund University Diabetes Centre (LUDC), Lund, Sweden
| | - Petter Storm
- Department of Clinical Sciences, Clinical Research Centre, Lund University, Malmö, Sweden
- Lund University Diabetes Centre (LUDC), Lund, Sweden
- Department of Experimental Medical Science, Developmental and Regenerative Neurobiology, Wallenberg Neuroscience Center, Lund, Sweden
| | - Vikash Chandra
- Stem Cells and Metabolism Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland
| | - Gad Hatem
- Department of Clinical Sciences, Clinical Research Centre, Lund University, Malmö, Sweden
- Lund University Diabetes Centre (LUDC), Lund, Sweden
| | - Emilia Ottosson-Laakso
- Department of Clinical Sciences, Clinical Research Centre, Lund University, Malmö, Sweden
- Lund University Diabetes Centre (LUDC), Lund, Sweden
| | - Dina Mansour-Aly
- Department of Clinical Sciences, Clinical Research Centre, Lund University, Malmö, Sweden
- Lund University Diabetes Centre (LUDC), Lund, Sweden
| | - Ulrika Krus
- Department of Clinical Sciences, Clinical Research Centre, Lund University, Malmö, Sweden
- Lund University Diabetes Centre (LUDC), Lund, Sweden
| | - Hazem Ibrahim
- Stem Cells and Metabolism Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland
| | - Emma Ahlqvist
- Department of Clinical Sciences, Clinical Research Centre, Lund University, Malmö, Sweden
- Lund University Diabetes Centre (LUDC), Lund, Sweden
| | - Tiinamaija Tuomi
- Department of Clinical Sciences, Clinical Research Centre, Lund University, Malmö, Sweden
- Lund University Diabetes Centre (LUDC), Lund, Sweden
- Department of Endocrinology, Abdominal Centre, Helsinki University Hospital, Folkhalsan Research Center, Helsinki, Finland
- Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland
| | - Erik Renström
- Department of Clinical Sciences, Clinical Research Centre, Lund University, Malmö, Sweden
- Lund University Diabetes Centre (LUDC), Lund, Sweden
| | - Olle Korsgren
- Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden
- Department of Clinical Chemistry and Transfusion Medicine, Institute of Biomedicine, University of Gothenburg, Gothenburg, Sweden
| | - Nils Wierup
- Department of Clinical Sciences, Clinical Research Centre, Lund University, Malmö, Sweden
- Lund University Diabetes Centre (LUDC), Lund, Sweden
| | - Mark Ibberson
- Vital-IT Group, SIB Swiss Institute of Bioinformatics, Lausanne, Switzerland
| | - Michele Solimena
- Paul Langerhans Institute Dresden of the Helmholtz Center, Munich at University Hospital Carl Gustav Carus and Faculty of Medicine, TU Dresden, Dresden, Germany
- German Center for Diabetes Research (DZD), Munich, Germany
- Max Planck Institute of Molecular Cell Biology and Genetics, (MPI-CBG), Dresden, Germany
| | - Piero Marchetti
- Department of Clinical and Experimental Medicine, Cisanello, University Hospital, University of Pisa, Pisa, Italy
| | - Claes Wollheim
- Department of Clinical Sciences, Clinical Research Centre, Lund University, Malmö, Sweden
- Lund University Diabetes Centre (LUDC), Lund, Sweden
- Department of Cell Physiology and Metabolism, Faculty of Medicine, University of Geneva, Geneva, Switzerland
| | - Isabella Artner
- Department of Clinical Sciences, Clinical Research Centre, Lund University, Malmö, Sweden
- Lund University Diabetes Centre (LUDC), Lund, Sweden
| | - Hindrik Mulder
- Department of Clinical Sciences, Clinical Research Centre, Lund University, Malmö, Sweden
- Lund University Diabetes Centre (LUDC), Lund, Sweden
| | - Ola Hansson
- Department of Clinical Sciences, Clinical Research Centre, Lund University, Malmö, Sweden
- Lund University Diabetes Centre (LUDC), Lund, Sweden
- Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland
| | - Timo Otonkoski
- Stem Cells and Metabolism Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland
- Children's Hospital, Helsinki University Hospital, Helsinki, Finland
| | - Leif Groop
- Department of Clinical Sciences, Clinical Research Centre, Lund University, Malmö, Sweden
- Lund University Diabetes Centre (LUDC), Lund, Sweden
- Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland
| | - Rashmi B Prasad
- Department of Clinical Sciences, Clinical Research Centre, Lund University, Malmö, Sweden
- Lund University Diabetes Centre (LUDC), Lund, Sweden
- Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland
- Human Tissue Laboratory at Lund University Diabetes Centre, Lund, Sweden
| |
Collapse
|
4
|
Cataldo LR, Singh T, Achanta K, Bsharat S, Prasad RB, Luan C, Renström E, Eliasson L, Artner I. MAFA and MAFB regulate exocytosis-related genes in human β-cells. Acta Physiol (Oxf) 2022; 234:e13761. [PMID: 34978761 DOI: 10.1111/apha.13761] [Citation(s) in RCA: 6] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/24/2021] [Revised: 12/22/2021] [Accepted: 01/01/2022] [Indexed: 12/13/2022]
Abstract
AIMS Reduced expression of exocytotic genes is associated with functional defects in insulin exocytosis contributing to impaired insulin secretion and type 2 diabetes (T2D) development. MAFA and MAFB transcription factors regulate β-cell physiology, and their gene expression is reduced in T2D β cells. We investigate if loss of MAFA and MAFB in human β cells contributes to T2D progression by regulating genes required for insulin exocytosis. METHODS Three approaches were performed: (1) RNAseq analysis with the focus on exocytosis-related genes in MafA-/- mouse islets, (2) correlational analysis between MAFA, MAFB and exocytosis-related genes in human islets and (3) MAFA and MAFB silencing in human islets and EndoC-βH1 cells followed by functional in vitro studies. RESULTS The expression of 30 exocytosis-related genes was significantly downregulated in MafA-/- mouse islets. In human islets, the expression of 29 exocytosis-related genes correlated positively with MAFA and MAFB. Eight exocytosis-related genes were downregulated in MafA-/- mouse islets and positively correlated with MAFA and MAFB in human islets. From this analysis, the expression of RAB3A, STXBP1, UNC13A, VAMP2, NAPA, NSF, STX1A and SYT7 was quantified after acute MAFA or MAFB silencing in EndoC-βH1 cells and human islets. MAFA and MAFB silencing resulted in impaired insulin secretion and reduced STX1A, SYT7 and STXBP1 (EndoC-βH1) and STX1A (human islets) mRNA expression. STX1A and STXBP1 protein expression was also impaired in islets from T2D donors which lack MAFA expression. CONCLUSION Our data indicate that STXBP1 and STX1A are important MAFA/B-regulated exocytosis genes which may contribute to insulin exocytosis defects observed in MAFA-deficient human T2D β cells.
Collapse
Affiliation(s)
- Luis Rodrigo Cataldo
- Endocrine Cell Differentiation and Function Group Stem Cell Centre Lund University Lund Sweden
- Lund University Diabetes Centre Clinical Research Center Malmo Sweden
- The Novo Nordisk Foundation Centre for Basic Metabolic Research Faculty of Health and Medical Sciences University of Copenhagen Copenhagen Denmark
| | - Tania Singh
- Endocrine Cell Differentiation and Function Group Stem Cell Centre Lund University Lund Sweden
- Lund University Diabetes Centre Clinical Research Center Malmo Sweden
| | - Kavya Achanta
- Endocrine Cell Differentiation and Function Group Stem Cell Centre Lund University Lund Sweden
- Lund University Diabetes Centre Clinical Research Center Malmo Sweden
| | - Sara Bsharat
- Endocrine Cell Differentiation and Function Group Stem Cell Centre Lund University Lund Sweden
- Lund University Diabetes Centre Clinical Research Center Malmo Sweden
| | - Rashmi B. Prasad
- Lund University Diabetes Centre Clinical Research Center Malmo Sweden
- Department of Clinical Sciences in Malmö Malmo Sweden
| | - Cheng Luan
- Lund University Diabetes Centre Clinical Research Center Malmo Sweden
| | - Erik Renström
- Lund University Diabetes Centre Clinical Research Center Malmo Sweden
| | - Lena Eliasson
- Lund University Diabetes Centre Clinical Research Center Malmo Sweden
- Department of Clinical Sciences in Malmö Malmo Sweden
- Islet Cell Exocytosis Lund University Lund Sweden
| | - Isabella Artner
- Endocrine Cell Differentiation and Function Group Stem Cell Centre Lund University Lund Sweden
- Lund University Diabetes Centre Clinical Research Center Malmo Sweden
| |
Collapse
|
5
|
Bompada P, Goncalves I, Wu C, Gao R, Sun J, Mir BA, Luan C, Renström E, Groop L, Weng J, Hansson O, Edsfeldt A, De Marinis Y. Epigenome-Wide Histone Acetylation Changes in Peripheral Blood Mononuclear Cells in Patients with Type 2 Diabetes and Atherosclerotic Disease. Biomedicines 2021; 9:biomedicines9121908. [PMID: 34944721 PMCID: PMC8698994 DOI: 10.3390/biomedicines9121908] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/29/2021] [Revised: 11/30/2021] [Accepted: 12/06/2021] [Indexed: 11/16/2022] Open
Abstract
There is emerging evidence of an association between epigenetic modifications, glycemic control and atherosclerosis risk. In this study, we mapped genome-wide epigenetic changes in patients with type 2 diabetes (T2D) and advanced atherosclerotic disease. We performed chromatin immunoprecipitation sequencing (ChIP-seq) using a histone 3 lysine 9 acetylation (H3K9ac) mark in peripheral blood mononuclear cells from patients with atherosclerosis with T2D (n = 8) or without T2D (ND, n = 10). We mapped epigenome changes and identified 23,394 and 13,133 peaks in ND and T2D individuals, respectively. Out of all the peaks, 753 domains near the transcription start site (TSS) were unique to T2D. We found that T2D in atherosclerosis leads to an H3K9ac increase in 118, and loss in 63 genomic regions. Furthermore, we discovered an association between the genomic locations of significant H3K9ac changes with genetic variants identified in previous T2D GWAS. The transcription factor 7-like 2 (TCF7L2) rs7903146, together with several human leukocyte antigen (HLA) variants, were among the domains with the most dramatic changes of H3K9ac enrichments. Pathway analysis revealed multiple activated pathways involved in immunity, including type 1 diabetes. Our results present novel evidence on the interaction between genetics and epigenetics, as well as epigenetic changes related to immunity in patients with T2D and advanced atherosclerotic disease.
Collapse
Affiliation(s)
- Pradeep Bompada
- Department of Clinical Sciences, Lund University, 20502 Malmö, Sweden; (P.B.); (C.W.); (B.A.M.); (C.L.); (E.R.); (L.G.); (O.H.)
| | - Isabel Goncalves
- Cardiovascular Research-Translational Studies, Institution of Clinical Science Malmö, Lund University, 20502 Malmö, Sweden; (I.G.); (J.S.); (A.E.)
- Department of Cardiology, Skåne University Hospital, 20502 Malmö, Sweden
| | - Chuanyan Wu
- Department of Clinical Sciences, Lund University, 20502 Malmö, Sweden; (P.B.); (C.W.); (B.A.M.); (C.L.); (E.R.); (L.G.); (O.H.)
- School of Control Science and Engineering, Shandong University, Jinan 250061, China
- School of Intelligent Engineering, Shandong Management University, Jinan 250100, China
| | - Rui Gao
- School of Control Science and Engineering, Shandong University, Jinan 250061, China
- Correspondence: (R.G.); (Y.D.M.); Tel.: +86-135-0531-8418 (R.G.); +46-760-384-868 (Y.D.M.)
| | - Jiangming Sun
- Cardiovascular Research-Translational Studies, Institution of Clinical Science Malmö, Lund University, 20502 Malmö, Sweden; (I.G.); (J.S.); (A.E.)
| | - Bilal Ahmad Mir
- Department of Clinical Sciences, Lund University, 20502 Malmö, Sweden; (P.B.); (C.W.); (B.A.M.); (C.L.); (E.R.); (L.G.); (O.H.)
| | - Cheng Luan
- Department of Clinical Sciences, Lund University, 20502 Malmö, Sweden; (P.B.); (C.W.); (B.A.M.); (C.L.); (E.R.); (L.G.); (O.H.)
| | - Erik Renström
- Department of Clinical Sciences, Lund University, 20502 Malmö, Sweden; (P.B.); (C.W.); (B.A.M.); (C.L.); (E.R.); (L.G.); (O.H.)
| | - Leif Groop
- Department of Clinical Sciences, Lund University, 20502 Malmö, Sweden; (P.B.); (C.W.); (B.A.M.); (C.L.); (E.R.); (L.G.); (O.H.)
- Finnish Institute for Molecular Medicine, University of Helsinki, 00290 Helsinki, Finland
| | - Jianping Weng
- Clinical Research Hospital, Chinese Academy of Sciences, Hefei 230001, China;
- Department of Endocrinology and Metabolism, Division of Life Sciences of Medicine, University of Science and Technology of China, Hefei 230001, China
| | - Ola Hansson
- Department of Clinical Sciences, Lund University, 20502 Malmö, Sweden; (P.B.); (C.W.); (B.A.M.); (C.L.); (E.R.); (L.G.); (O.H.)
- Institute for Molecular Medicine Finland (FIMM), Helsinki University, 00290 Helsinki, Finland
| | - Andreas Edsfeldt
- Cardiovascular Research-Translational Studies, Institution of Clinical Science Malmö, Lund University, 20502 Malmö, Sweden; (I.G.); (J.S.); (A.E.)
- Department of Cardiology, Skåne University Hospital, 20502 Malmö, Sweden
- Wallenberg Center for Molecular Medicine, Lund University, 20502 Malmö, Sweden
| | - Yang De Marinis
- Department of Clinical Sciences, Lund University, 20502 Malmö, Sweden; (P.B.); (C.W.); (B.A.M.); (C.L.); (E.R.); (L.G.); (O.H.)
- School of Control Science and Engineering, Shandong University, Jinan 250061, China
- Clinical Research Hospital, Chinese Academy of Sciences, Hefei 230001, China;
- Department of Endocrinology and Metabolism, Division of Life Sciences of Medicine, University of Science and Technology of China, Hefei 230001, China
- Correspondence: (R.G.); (Y.D.M.); Tel.: +86-135-0531-8418 (R.G.); +46-760-384-868 (Y.D.M.)
| |
Collapse
|
6
|
Wu C, Borné Y, Gao R, López Rodriguez M, Roell WC, Wilson JM, Regmi A, Luan C, Aly DM, Peter A, Machann J, Staiger H, Fritsche A, Birkenfeld AL, Tao R, Wagner R, Canouil M, Hong MG, Schwenk JM, Ahlqvist E, Kaikkonen MU, Nilsson P, Shore AC, Khan F, Natali A, Melander O, Orho-Melander M, Nilsson J, Häring HU, Renström E, Wollheim CB, Engström G, Weng J, Pearson ER, Franks PW, White MF, Duffin KL, Vaag AA, Laakso M, Stefan N, Groop L, De Marinis Y. Elevated circulating follistatin associates with an increased risk of type 2 diabetes. Nat Commun 2021; 12:6486. [PMID: 34759311 PMCID: PMC8580990 DOI: 10.1038/s41467-021-26536-w] [Citation(s) in RCA: 30] [Impact Index Per Article: 10.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/19/2020] [Accepted: 10/05/2021] [Indexed: 12/23/2022] Open
Abstract
The hepatokine follistatin is elevated in patients with type 2 diabetes (T2D) and promotes hyperglycemia in mice. Here we explore the relationship of plasma follistatin levels with incident T2D and mechanisms involved. Adjusted hazard ratio (HR) per standard deviation (SD) increase in follistatin levels for T2D is 1.24 (CI: 1.04–1.47, p < 0.05) during 19-year follow-up (n = 4060, Sweden); and 1.31 (CI: 1.09–1.58, p < 0.01) during 4-year follow-up (n = 883, Finland). High circulating follistatin associates with adipose tissue insulin resistance and non-alcoholic fatty liver disease (n = 210, Germany). In human adipocytes, follistatin dose-dependently increases free fatty acid release. In genome-wide association study (GWAS), variation in the glucokinase regulatory protein gene (GCKR) associates with plasma follistatin levels (n = 4239, Sweden; n = 885, UK, Italy and Sweden) and GCKR regulates follistatin secretion in hepatocytes in vitro. Our findings suggest that GCKR regulates follistatin secretion and that elevated circulating follistatin associates with an increased risk of T2D by inducing adipose tissue insulin resistance. Follistatin promotes in type 2 diabetes (T2D) pathogenesis in model animals and is elevated in patients with T2D. Here the authors report that plasma follistatin associates with increased risk of incident T2D in two longitudinal cohorts, and show that follistatin regulates insulin-induced suppression lipolysis in cultured human adipocytes.
Collapse
Affiliation(s)
- Chuanyan Wu
- Department of Clinical Sciences, Lund University, Malmö, Sweden.,School of Control Science and Engineering, Shandong University, Jinan, Shandong, China.,School of Intelligent Engineering, Shandong Management University, Jinan, Shandong, China
| | - Yan Borné
- Department of Clinical Sciences, Lund University, Malmö, Sweden
| | - Rui Gao
- School of Control Science and Engineering, Shandong University, Jinan, Shandong, China
| | - Maykel López Rodriguez
- Institute of Clinical Medicine, Internal Medicine, University of Eastern Finland, Kuopio, Finland.,A.I. Virtanen Institute for Molecular Sciences, Department of Biotechnology and Molecular Medicine, University of Eastern Finland, Kuopio, Finland
| | - William C Roell
- Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA
| | - Jonathan M Wilson
- Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA
| | - Ajit Regmi
- Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA
| | - Cheng Luan
- Department of Clinical Sciences, Lund University, Malmö, Sweden
| | | | - Andreas Peter
- Department of Internal Medicine IV, Division of Endocrinology, Diabetology and Nephrology; and Department for Diagnostic Laboratory Medicine, Institute for Clinical Chemistry and Pathobiochemistry, University Hospital Tübingen, University of Tübingen, Tübingen, Germany.,Institute of Diabetes Research and Metabolic Diseases (IDM) of the Helmholtz Center Munich, Tübingen, Germany.,German Center for Diabetes Research (DZD), Tübingen, Germany
| | - Jürgen Machann
- Institute of Diabetes Research and Metabolic Diseases (IDM) of the Helmholtz Center Munich, Tübingen, Germany.,German Center for Diabetes Research (DZD), Tübingen, Germany.,Section of Experimental Radiology, Department of Radiology, University of Tübingen, Tübingen, Germany
| | - Harald Staiger
- Department of Internal Medicine IV, Division of Endocrinology, Diabetology and Nephrology; and Department for Diagnostic Laboratory Medicine, Institute for Clinical Chemistry and Pathobiochemistry, University Hospital Tübingen, University of Tübingen, Tübingen, Germany.,Institute of Diabetes Research and Metabolic Diseases (IDM) of the Helmholtz Center Munich, Tübingen, Germany.,German Center for Diabetes Research (DZD), Tübingen, Germany
| | - Andreas Fritsche
- Department of Internal Medicine IV, Division of Endocrinology, Diabetology and Nephrology; and Department for Diagnostic Laboratory Medicine, Institute for Clinical Chemistry and Pathobiochemistry, University Hospital Tübingen, University of Tübingen, Tübingen, Germany.,Institute of Diabetes Research and Metabolic Diseases (IDM) of the Helmholtz Center Munich, Tübingen, Germany.,German Center for Diabetes Research (DZD), Tübingen, Germany
| | - Andreas L Birkenfeld
- Department of Internal Medicine IV, Division of Endocrinology, Diabetology and Nephrology; and Department for Diagnostic Laboratory Medicine, Institute for Clinical Chemistry and Pathobiochemistry, University Hospital Tübingen, University of Tübingen, Tübingen, Germany.,Institute of Diabetes Research and Metabolic Diseases (IDM) of the Helmholtz Center Munich, Tübingen, Germany.,German Center for Diabetes Research (DZD), Tübingen, Germany
| | - Rongya Tao
- Division of Endocrinology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA
| | - Robert Wagner
- Department of Internal Medicine IV, Division of Endocrinology, Diabetology and Nephrology; and Department for Diagnostic Laboratory Medicine, Institute for Clinical Chemistry and Pathobiochemistry, University Hospital Tübingen, University of Tübingen, Tübingen, Germany.,Institute of Diabetes Research and Metabolic Diseases (IDM) of the Helmholtz Center Munich, Tübingen, Germany.,German Center for Diabetes Research (DZD), Tübingen, Germany
| | - Mickaël Canouil
- Inserm U1283 / CNRS UMR 8199, European Genomic Institute for Diabetes (EGID), Institut Pasteur de Lille; University of Lille, Lille University Hospital, Lille, France
| | - Mun-Gwan Hong
- Affinity Proteomics, Science for Life Laboratory, KTH Royal Institute of Technology, Stockholm, Sweden
| | - Jochen M Schwenk
- Affinity Proteomics, Science for Life Laboratory, KTH Royal Institute of Technology, Stockholm, Sweden
| | - Emma Ahlqvist
- Department of Clinical Sciences, Lund University, Malmö, Sweden
| | - Minna U Kaikkonen
- A.I. Virtanen Institute for Molecular Sciences, Department of Biotechnology and Molecular Medicine, University of Eastern Finland, Kuopio, Finland
| | - Peter Nilsson
- Department of Clinical Sciences, Lund University, Malmö, Sweden
| | - Angela C Shore
- NIHR Exeter Clinical Research Facility, Royal Devon and Exeter Hospital and University of Exeter Medical School, Exeter, Devon, UK
| | - Faisel Khan
- Division of Systems Medicine, University of Dundee, Ninewells Hospital & Medical School, Dundee, UK
| | - Andrea Natali
- Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy
| | - Olle Melander
- Department of Clinical Sciences, Lund University, Malmö, Sweden
| | | | - Jan Nilsson
- Department of Clinical Sciences, Lund University, Malmö, Sweden
| | - Hans-Ulrich Häring
- Department of Internal Medicine IV, Division of Endocrinology, Diabetology and Nephrology; and Department for Diagnostic Laboratory Medicine, Institute for Clinical Chemistry and Pathobiochemistry, University Hospital Tübingen, University of Tübingen, Tübingen, Germany.,Institute of Diabetes Research and Metabolic Diseases (IDM) of the Helmholtz Center Munich, Tübingen, Germany.,German Center for Diabetes Research (DZD), Tübingen, Germany
| | - Erik Renström
- Department of Clinical Sciences, Lund University, Malmö, Sweden
| | - Claes B Wollheim
- Department of Clinical Sciences, Lund University, Malmö, Sweden.,Department of Cell Physiology and Metabolism, University Medical Centre, Geneva, Switzerland
| | - Gunnar Engström
- Department of Clinical Sciences, Lund University, Malmö, Sweden
| | - Jianping Weng
- Department of Endocrinology and Metabolism, Division of Life Sciences of Medicine, University of Science and Technology of China, Hefei, China
| | - Ewan R Pearson
- Division of Population Health & Genomics, School of Medicine, University of Dundee, Dundee, DD1 9SY, UK
| | - Paul W Franks
- Department of Clinical Sciences, Lund University, Malmö, Sweden
| | - Morris F White
- Division of Endocrinology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA
| | - Kevin L Duffin
- Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA
| | | | - Markku Laakso
- Institute of Clinical Medicine, Internal Medicine, University of Eastern Finland, Kuopio, Finland.,Department of Medicine, Kuopio University Hospital, Kuopio, Finland
| | - Norbert Stefan
- Department of Internal Medicine IV, Division of Endocrinology, Diabetology and Nephrology; and Department for Diagnostic Laboratory Medicine, Institute for Clinical Chemistry and Pathobiochemistry, University Hospital Tübingen, University of Tübingen, Tübingen, Germany.,Institute of Diabetes Research and Metabolic Diseases (IDM) of the Helmholtz Center Munich, Tübingen, Germany.,German Center for Diabetes Research (DZD), Tübingen, Germany
| | - Leif Groop
- Department of Clinical Sciences, Lund University, Malmö, Sweden.,Finnish Institute for Molecular Medicine, University of Helsinki, Helsinki, Finland
| | - Yang De Marinis
- Department of Clinical Sciences, Lund University, Malmö, Sweden. .,School of Control Science and Engineering, Shandong University, Jinan, Shandong, China. .,Department of Endocrinology and Metabolism, Division of Life Sciences of Medicine, University of Science and Technology of China, Hefei, China.
| |
Collapse
|
7
|
Cataldo LR, Vishnu N, Singh T, Bertonnier-Brouty L, Bsharat S, Luan C, Renström E, Prasad RB, Fex M, Mulder H, Artner I. The MafA-target gene PPP1R1A regulates GLP1R-mediated amplification of glucose-stimulated insulin secretion in β-cells. Metabolism 2021; 118:154734. [PMID: 33631146 DOI: 10.1016/j.metabol.2021.154734] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/29/2020] [Revised: 02/07/2021] [Accepted: 02/15/2021] [Indexed: 12/11/2022]
Abstract
The amplification of glucose-stimulated insulin secretion (GSIS) through incretin signaling is critical for maintaining physiological glucose levels. Incretins, like glucagon-like peptide 1 (GLP1), are a target of type 2 diabetes drugs aiming to enhance insulin secretion. Here we show that the protein phosphatase 1 inhibitor protein 1A (PPP1R1A), is expressed in β-cells and that its expression is reduced in dysfunctional β-cells lacking MafA and upon acute MafA knock down. MafA is a central regulator of GSIS and β-cell function. We observed a strong correlation of MAFA and PPP1R1A mRNA levels in human islets, moreover, PPP1R1A mRNA levels were reduced in type 2 diabetic islets and positively correlated with GLP1-mediated GSIS amplification. PPP1R1A silencing in INS1 (832/13) β-cells impaired GSIS amplification, PKA-target protein phosphorylation, mitochondrial coupling efficiency and also the expression of critical β-cell marker genes like MafA, Pdx1, NeuroD1 and Pax6. Our results demonstrate that the β-cell transcription factor MafA is required for PPP1R1A expression and that reduced β-cell PPP1R1A levels impaired β-cell function and contributed to β-cell dedifferentiation during type 2 diabetes. Loss of PPP1R1A in type 2 diabetic β-cells may explains the unresponsiveness of type 2 diabetic patients to GLP1R-based treatments.
Collapse
Affiliation(s)
- Luis Rodrigo Cataldo
- Endocrine Cell Differentiation and Function group, Stem Cell Centre, Lund University, Sweden; Lund University Diabetes Centre, Clinical Research Center, Sweden.
| | - Neelanjan Vishnu
- Lund University Diabetes Centre, Clinical Research Center, Sweden
| | - Tania Singh
- Endocrine Cell Differentiation and Function group, Stem Cell Centre, Lund University, Sweden; Lund University Diabetes Centre, Clinical Research Center, Sweden
| | - Ludivine Bertonnier-Brouty
- Endocrine Cell Differentiation and Function group, Stem Cell Centre, Lund University, Sweden; Lund University Diabetes Centre, Clinical Research Center, Sweden
| | - Sara Bsharat
- Endocrine Cell Differentiation and Function group, Stem Cell Centre, Lund University, Sweden; Lund University Diabetes Centre, Clinical Research Center, Sweden
| | - Cheng Luan
- Lund University Diabetes Centre, Clinical Research Center, Sweden
| | - Erik Renström
- Lund University Diabetes Centre, Clinical Research Center, Sweden
| | - Rashmi B Prasad
- Lund University Diabetes Centre, Clinical Research Center, Sweden; Department of Clinical Sciences in Malmö, Sweden
| | - Malin Fex
- Lund University Diabetes Centre, Clinical Research Center, Sweden
| | - Hindrik Mulder
- Lund University Diabetes Centre, Clinical Research Center, Sweden
| | - Isabella Artner
- Endocrine Cell Differentiation and Function group, Stem Cell Centre, Lund University, Sweden; Lund University Diabetes Centre, Clinical Research Center, Sweden.
| |
Collapse
|
8
|
Seiron P, Stenwall A, Hedin A, Granlund L, Esguerra JLS, Volkov P, Renström E, Korsgren O, Lundberg M, Skog O. Transcriptional analysis of islets of Langerhans from organ donors of different ages. PLoS One 2021; 16:e0247888. [PMID: 33711030 PMCID: PMC7954335 DOI: 10.1371/journal.pone.0247888] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/19/2020] [Accepted: 02/15/2021] [Indexed: 12/13/2022] Open
Abstract
Insulin secretion is impaired with increasing age. In this study, we aimed to determine whether aging induces specific transcriptional changes in human islets. Laser capture microdissection was used to extract pancreatic islet tissue from 37 deceased organ donors aged 1-81 years. The transcriptomes of the extracted islets were analysed using Ion AmpliSeq sequencing. 346 genes that co-vary significantly with age were found. There was an increased transcription of genes linked to senescence, and several aspects of the cell cycle machinery were downregulated with increasing age. We detected numerous genes not linked to aging in previous studies likely because earlier studies analysed islet cells isolated by enzymatic digestion which might affect the islet transcriptome. Among the novel genes demonstrated to correlate with age, we found an upregulation of SPP1 encoding osteopontin. In beta cells, osteopontin has been seen to be protective against both cytotoxicity and hyperglycaemia. In summary, we present a transcriptional profile of aging in human islets and identify genes that could affect disease course in diabetes.
Collapse
Affiliation(s)
- Peter Seiron
- Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden
| | - Anton Stenwall
- Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden
| | - Anders Hedin
- Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden
| | - Louise Granlund
- Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden
| | | | - Petr Volkov
- Department of Clinical Sciences-Malmö, Lund University Diabetes Centre, Malmö, Sweden
| | - Erik Renström
- Department of Clinical Sciences-Malmö, Lund University Diabetes Centre, Malmö, Sweden
| | - Olle Korsgren
- Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden
- Institute of Medicine, University of Gothenburg, Gothenburg, Sweden
| | - Marcus Lundberg
- Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden
| | - Oskar Skog
- Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden
| |
Collapse
|
9
|
Ye Y, Barghouth M, Luan C, Kazim A, Zhou Y, Eliasson L, Zhang E, Hansson O, Thevenin T, Renström E. The TCF7L2-dependent high-voltage activated calcium channel subunit α2δ-1 controls calcium signaling in rodent pancreatic beta-cells. Mol Cell Endocrinol 2020; 502:110673. [PMID: 31805307 DOI: 10.1016/j.mce.2019.110673] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/26/2019] [Revised: 11/19/2019] [Accepted: 11/30/2019] [Indexed: 12/16/2022]
Abstract
The transcription factor TCF7L2 remains the most important diabetes gene identified to date and genetic risk carriers exhibit lower insulin secretion. We show that Tcf7l2 regulates the auxiliary subunit of voltage-gated Ca2+ channels, Cacna2d1 gene/α2δ-1 protein levels. Furthermore, suppression of α2δ-1 decreased voltage-gated Ca2+ currents and high glucose/depolarization-evoked Ca2+ signaling which mimicked the effect of silencing of Tcf7l2. This appears to be the result of impaired voltage-gated Ca2+ channel trafficking to the plasma membrane, as Cav1.2 channels accumulated in the recycling endosomes after α2δ-1 suppression, in clonal as well as primary rodent beta-cells. This impaired the capacity for glucose-induced insulin secretion in Cacna2d1-silenced cells. Overexpression of α2δ-1 increased high-glucose/K+-stimulated insulin secretion. Furthermore, overexpression of α2δ-1 in Tcf7l2-silenced cells rescued the Tcf7l2-dependent impairment of Ca2+ signaling, but not the reduced insulin secretion. Taken together, these data clarify the connection between Tcf7l2, α2δ-1 in Ca2+-dependent insulin secretion.
Collapse
Affiliation(s)
- Yingying Ye
- Lund University, Department of Clinical Sciences, Islet Pathophysiology Group, Sweden
| | - Mohammad Barghouth
- Lund University, Department of Clinical Sciences, Islet Pathophysiology Group, Sweden
| | - Cheng Luan
- Lund University, Department of Clinical Sciences, Islet Pathophysiology Group, Sweden
| | - Abdulla Kazim
- Lund University, Department of Clinical Sciences, Islet Pathophysiology Group, Sweden
| | - Yuedan Zhou
- Lund University, Department of Clinical Sciences, Diabetes and Endocrinology Group, Sweden
| | - Lena Eliasson
- Lund University, Department of Clinical Sciences, Islet Pathophysiology Group, Sweden
| | - Enming Zhang
- Lund University, Department of Clinical Sciences, Islet Pathophysiology Group, Sweden
| | - Ola Hansson
- Lund University, Department of Clinical Sciences, Diabetes and Endocrinology Group, Sweden
| | - Thomas Thevenin
- Lund University, Department of Clinical Sciences, Islet Pathophysiology Group, Sweden
| | - Erik Renström
- Lund University, Department of Clinical Sciences, Islet Pathophysiology Group, Sweden.
| |
Collapse
|
10
|
Golec E, Rosberg R, Zhang E, Renström E, Blom AM, King BC. A cryptic non-GPI-anchored cytosolic isoform of CD59 controls insulin exocytosis in pancreatic β-cells by interaction with SNARE proteins. FASEB J 2019; 33:12425-12434. [PMID: 31412214 DOI: 10.1096/fj.201901007r] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Abstract
CD59 is a glycosylphosphatidylinositol (GPI)-anchored cell surface inhibitor of the complement membrane attack complex (MAC). We showed previously that CD59 is highly expressed in pancreatic islets but is down-regulated in rodent models of diabetes. CD59 knockdown but not enzymatic removal of cell surface CD59 led to a loss of glucose-stimulated insulin secretion (GSIS), suggesting that an intracellular pool of CD59 is required. In this current paper, we now report that non-GPI-anchored CD59 is present in the cytoplasm, colocalizes with exocytotic protein vesicle-associated membrane protein 2, and completely rescues GSIS in cells lacking endogenous CD59 expression. The involvement of cytosolic non-GPI-anchored CD59 in GSIS is supported in phosphatidylinositol glycan class A knockout GPI anchor-deficient β-cells, in which GSIS is still CD59 dependent. Furthermore, site-directed mutagenesis demonstrated different structural requirements of CD59 for its 2 functions, MAC inhibition and GSIS. Our results suggest that CD59 is retrotranslocated from the endoplasmic reticulum to the cytosol, a process mediated by recognition of trimmed N-linked oligosaccharides, supported by the partial glycosylation of non-GPI-anchored cytosolic CD59 as well as the failure of N-linked glycosylation site mutant CD59 to reach the cytosol or rescue GSIS. This study thus proposes the previously undescribed existence of non-GPI-anchored cytosolic CD59, which is required for insulin secretion.-Golec, E., Rosberg, R., Zhang, E., Renström, E., Blom, A. M., King, B. C. A cryptic non-GPI-anchored cytosolic isoform of CD59 controls insulin exocytosis in pancreatic β-cells by interaction with SNARE proteins.
Collapse
Affiliation(s)
- Ewelina Golec
- Section of Medical Protein Chemistry, Department of Translational Medicine, Lund University, Malmö, Sweden
| | - Rebecca Rosberg
- Section of Medical Protein Chemistry, Department of Translational Medicine, Lund University, Malmö, Sweden
| | - Enming Zhang
- Department of Clinical Sciences Malmö, Lund University Diabetes Centre, Malmö, Sweden
| | - Erik Renström
- Department of Clinical Sciences Malmö, Lund University Diabetes Centre, Malmö, Sweden
| | - Anna M Blom
- Section of Medical Protein Chemistry, Department of Translational Medicine, Lund University, Malmö, Sweden
| | - Ben C King
- Section of Medical Protein Chemistry, Department of Translational Medicine, Lund University, Malmö, Sweden
| |
Collapse
|
11
|
Affiliation(s)
- Erik Renström
- Lund University Diabetes Centre, Exodiab Strategic Research Area in Diabetes, Department of Clinical Sciences Malmö, Lund University, Lund, Sweden.
| | - Enming Zhang
- Lund University Diabetes Centre, Exodiab Strategic Research Area in Diabetes, Department of Clinical Sciences Malmö, Lund University, Lund, Sweden
| |
Collapse
|
12
|
Luan C, Ye Y, Singh T, Barghouth M, Eliasson L, Artner I, Zhang E, Renström E. The calcium channel subunit gamma-4 is regulated by MafA and necessary for pancreatic beta-cell specification. Commun Biol 2019; 2:106. [PMID: 30911681 PMCID: PMC6420573 DOI: 10.1038/s42003-019-0351-4] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/02/2018] [Accepted: 02/08/2019] [Indexed: 12/22/2022] Open
Abstract
Voltage-gated Ca2+ (CaV) channels trigger glucose-induced insulin secretion in pancreatic beta-cell and their dysfunction increases diabetes risk. These heteromeric complexes include the main subunit alpha1, and the accessory ones, including subunit gamma that remains unexplored. Here, we demonstrate that CaV gamma subunit 4 (CaVγ4) is downregulated in islets from human donors with diabetes, diabetic Goto-Kakizaki (GK) rats, as well as under conditions of gluco-/lipotoxic stress. Reduction of CaVγ4 expression results in decreased expression of L-type CaV1.2 and CaV1.3, thereby suppressing voltage-gated Ca2+ entry and glucose stimulated insulin exocytosis. The most important finding is that CaVγ4 expression is controlled by the transcription factor responsible for beta-cell specification, MafA, as verified by chromatin immunoprecipitation and experiments in beta-cell specific MafA knockout mice (MafA Δβcell ). Taken together, these findings suggest that CaVγ4 is necessary for maintaining a functional differentiated beta-cell phenotype. Treatment aiming at restoring CaVγ4 may help to restore beta-cell function in diabetes.
Collapse
Affiliation(s)
- Cheng Luan
- Lund University Diabetes Center, Department of Clinical Sciences Malmö, Lund University, 202 13 Malmö, Sweden
| | - Yingying Ye
- Lund University Diabetes Center, Department of Clinical Sciences Malmö, Lund University, 202 13 Malmö, Sweden
| | - Tania Singh
- Stem Cell Center, Department of Laboratory Medicine, Lund University, 221 85 Lund, Sweden
| | - Mohammad Barghouth
- Lund University Diabetes Center, Department of Clinical Sciences Malmö, Lund University, 202 13 Malmö, Sweden
| | - Lena Eliasson
- Lund University Diabetes Center, Department of Clinical Sciences Malmö, Lund University, 202 13 Malmö, Sweden
| | - Isabella Artner
- Lund University Diabetes Center, Department of Clinical Sciences Malmö, Lund University, 202 13 Malmö, Sweden
- Stem Cell Center, Department of Laboratory Medicine, Lund University, 221 85 Lund, Sweden
| | - Enming Zhang
- Lund University Diabetes Center, Department of Clinical Sciences Malmö, Lund University, 202 13 Malmö, Sweden
| | - Erik Renström
- Lund University Diabetes Center, Department of Clinical Sciences Malmö, Lund University, 202 13 Malmö, Sweden
| |
Collapse
|
13
|
King BC, Renström E, Blom AM. Intracellular cytosolic complement component C3 regulates cytoprotective autophagy in pancreatic beta cells by interaction with ATG16L1. Autophagy 2019; 15:919-921. [PMID: 30741587 DOI: 10.1080/15548627.2019.1580515] [Citation(s) in RCA: 27] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022] Open
Abstract
Complement component C3 is central to the complement system, a humoral effector mechanism of innate immune defense. When activated, C3 covalently binds to target particles, marking them for uptake and clearance by phagocytosis. We now show that C3 also exists within the cytosol where it interacts with ATG16L1, and is therefore involved in the intracellular clearance and recycling of material by macroautophagy/autophagy in pancreatic beta cells. C3 is highly expressed in isolated human islets, and its expression is upregulated in islets isolated from diabetic patients and rodents, and correlates with patient HBA1c and body mass index (BMI). Knockout of C3 in clonal beta cells leads to dysfunctional autophagy, and increased cell death after challenge with diabetogenic stresses, which are usually alleviated by increased autophagic turnover. However, autophagic degradation of INS (insulin) granules regulates total INS content, and increased autophagy due to C3 upregulation may deplete beta cell INS stores. C3 is therefore required for efficient autophagic turnover in beta cells, and is upregulated as a cytoprotective factor during diabetes.
Collapse
Affiliation(s)
- Ben C King
- a Department of Translational Medicine , Lund University , Malmö , Sweden
| | - Erik Renström
- b Lund University Diabetes Centre, Department of Clinical Sciences Malmö , Lund University , Malmö , Sweden
| | - Anna M Blom
- a Department of Translational Medicine , Lund University , Malmö , Sweden
| |
Collapse
|
14
|
King BC, Kulak K, Krus U, Rosberg R, Golec E, Wozniak K, Gomez MF, Zhang E, O'Connell DJ, Renström E, Blom AM. Complement Component C3 Is Highly Expressed in Human Pancreatic Islets and Prevents β Cell Death via ATG16L1 Interaction and Autophagy Regulation. Cell Metab 2019; 29:202-210.e6. [PMID: 30293775 DOI: 10.1016/j.cmet.2018.09.009] [Citation(s) in RCA: 87] [Impact Index Per Article: 17.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/24/2018] [Revised: 07/23/2018] [Accepted: 09/07/2018] [Indexed: 01/25/2023]
Abstract
We show here that human pancreatic islets highly express C3, which is both secreted and present in the cytosol. Within isolated human islets, C3 expression correlates with type 2 diabetes (T2D) donor status, HbA1c, and inflammation. Islet C3 expression is also upregulated in several rodent diabetes models. C3 interacts with ATG16L1, which is essential for autophagy. Autophagy relieves cellular stresses faced by β cells during T2D and maintains cellular homeostasis. C3 knockout in clonal β cells impaired autophagy and led to increased apoptosis after exposure of cells to palmitic acid and IAPP. In the absence of C3, autophagosomes do not undergo fusion with lysosomes. Thus, C3 may be upregulated in islets during T2D as a cytoprotective factor against β cell dysfunction caused by impaired autophagy. Therefore, we revealed a previously undescribed intracellular function for C3, connecting the complement system directly to autophagy, with a broad potential importance in other diseases and cell types.
Collapse
Affiliation(s)
- Ben C King
- Section of Medical Protein Chemistry, Department of Translational Medicine, Lund University, 214-28 Malmö, Sweden
| | - Klaudia Kulak
- Section of Medical Protein Chemistry, Department of Translational Medicine, Lund University, 214-28 Malmö, Sweden
| | - Ulrika Krus
- Lund University Diabetes Centre, Department of Clinical Sciences Malmö, Lund University, 214-28 Malmö, Sweden
| | - Rebecca Rosberg
- Section of Medical Protein Chemistry, Department of Translational Medicine, Lund University, 214-28 Malmö, Sweden
| | - Ewelina Golec
- Section of Medical Protein Chemistry, Department of Translational Medicine, Lund University, 214-28 Malmö, Sweden
| | - Katarzyna Wozniak
- Section of Medical Protein Chemistry, Department of Translational Medicine, Lund University, 214-28 Malmö, Sweden
| | - Maria F Gomez
- Lund University Diabetes Centre, Department of Clinical Sciences Malmö, Lund University, 214-28 Malmö, Sweden
| | - Enming Zhang
- Lund University Diabetes Centre, Department of Clinical Sciences Malmö, Lund University, 214-28 Malmö, Sweden
| | - David J O'Connell
- School of Biomolecular & Biomedical Science, Conway Institute, University College Dublin, Dublin, Ireland
| | - Erik Renström
- Lund University Diabetes Centre, Department of Clinical Sciences Malmö, Lund University, 214-28 Malmö, Sweden
| | - Anna M Blom
- Section of Medical Protein Chemistry, Department of Translational Medicine, Lund University, 214-28 Malmö, Sweden.
| |
Collapse
|
15
|
Zhang E, Mohammed Al-Amily I, Mohammed S, Luan C, Asplund O, Ahmed M, Ye Y, Ben-Hail D, Soni A, Vishnu N, Bompada P, De Marinis Y, Groop L, Shoshan-Barmatz V, Renström E, Wollheim CB, Salehi A. Preserving Insulin Secretion in Diabetes by Inhibiting VDAC1 Overexpression and Surface Translocation in β Cells. Cell Metab 2019; 29:64-77.e6. [PMID: 30293774 PMCID: PMC6331340 DOI: 10.1016/j.cmet.2018.09.008] [Citation(s) in RCA: 91] [Impact Index Per Article: 18.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/28/2018] [Revised: 07/12/2018] [Accepted: 09/08/2018] [Indexed: 02/08/2023]
Abstract
Type 2 diabetes (T2D) develops after years of prediabetes during which high glucose (glucotoxicity) impairs insulin secretion. We report that the ATP-conducting mitochondrial outer membrane voltage-dependent anion channel-1 (VDAC1) is upregulated in islets from T2D and non-diabetic organ donors under glucotoxic conditions. This is caused by a glucotoxicity-induced transcriptional program, triggered during years of prediabetes with suboptimal blood glucose control. Metformin counteracts VDAC1 induction. VDAC1 overexpression causes its mistargeting to the plasma membrane of the insulin-secreting β cells with loss of the crucial metabolic coupling factor ATP. VDAC1 antibodies and inhibitors prevent ATP loss. Through direct inhibition of VDAC1 conductance, metformin, like specific VDAC1 inhibitors and antibodies, restores the impaired generation of ATP and glucose-stimulated insulin secretion in T2D islets. Treatment of db/db mice with VDAC1 inhibitor prevents hyperglycemia, and maintains normal glucose tolerance and physiological regulation of insulin secretion. Thus, β cell function is preserved by targeting the novel diabetes executer protein VDAC1.
Collapse
Affiliation(s)
- Enming Zhang
- Department of Clinical Sciences, Malmö, Lund University, Jan Waldenströms Gata 35, Malmö 214 28, Sweden
| | - Israa Mohammed Al-Amily
- Department of Clinical Sciences, Malmö, Lund University, Jan Waldenströms Gata 35, Malmö 214 28, Sweden
| | - Sarheed Mohammed
- Department of Clinical Sciences, Malmö, Lund University, Jan Waldenströms Gata 35, Malmö 214 28, Sweden
| | - Cheng Luan
- Department of Clinical Sciences, Malmö, Lund University, Jan Waldenströms Gata 35, Malmö 214 28, Sweden
| | - Olof Asplund
- Department of Clinical Sciences, Malmö, Lund University, Jan Waldenströms Gata 35, Malmö 214 28, Sweden
| | - Meftun Ahmed
- Academic Hospital Uppsala University, Uppsala, Sweden
| | - Yingying Ye
- Department of Clinical Sciences, Malmö, Lund University, Jan Waldenströms Gata 35, Malmö 214 28, Sweden
| | - Danya Ben-Hail
- Department of Life Sciences and the National Institute for Biotechnology in the Negev, Ben-Gurion University of the Negev, Beer-Sheva 84105, Israel
| | - Arvind Soni
- Department of Clinical Sciences, Malmö, Lund University, Jan Waldenströms Gata 35, Malmö 214 28, Sweden
| | - Neelanjan Vishnu
- Department of Clinical Sciences, Malmö, Lund University, Jan Waldenströms Gata 35, Malmö 214 28, Sweden
| | - Pradeep Bompada
- Department of Clinical Sciences, Malmö, Lund University, Jan Waldenströms Gata 35, Malmö 214 28, Sweden
| | - Yang De Marinis
- Department of Clinical Sciences, Malmö, Lund University, Jan Waldenströms Gata 35, Malmö 214 28, Sweden
| | - Leif Groop
- Department of Clinical Sciences, Malmö, Lund University, Jan Waldenströms Gata 35, Malmö 214 28, Sweden; Finnish Institute for Molecular Medicine, Helsinki University, Helsinki, Finland
| | - Varda Shoshan-Barmatz
- Department of Life Sciences and the National Institute for Biotechnology in the Negev, Ben-Gurion University of the Negev, Beer-Sheva 84105, Israel
| | - Erik Renström
- Department of Clinical Sciences, Malmö, Lund University, Jan Waldenströms Gata 35, Malmö 214 28, Sweden
| | - Claes B Wollheim
- Department of Clinical Sciences, Malmö, Lund University, Jan Waldenströms Gata 35, Malmö 214 28, Sweden; Department of Cell Physiology and Metabolism, University Medical Centre, 1 rue Michel-Servet, Geneva 4, Switzerland.
| | - Albert Salehi
- Department of Clinical Sciences, Malmö, Lund University, Jan Waldenströms Gata 35, Malmö 214 28, Sweden.
| |
Collapse
|
16
|
Singh T, Sarmiento L, Luan C, Prasad RB, Johansson J, Cataldo LR, Renström E, Soneji S, Cilio C, Artner I. MafA Expression Preserves Immune Homeostasis in Human and Mouse Islets. Genes (Basel) 2018; 9:genes9120644. [PMID: 30567413 PMCID: PMC6315686 DOI: 10.3390/genes9120644] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/29/2018] [Accepted: 12/12/2018] [Indexed: 02/07/2023] Open
Abstract
Type 1 (T1D) and type 2 (T2D) diabetes are triggered by a combination of environmental and/or genetic factors. Maf transcription factors regulate pancreatic beta (β)-cell function, and have also been implicated in the regulation of immunomodulatory cytokines like interferon-β (IFNβ1). In this study, we assessed MAFA and MAFB co-expression with pro-inflammatory cytokine signaling genes in RNA-seq data from human pancreatic islets. Interestingly, MAFA expression was strongly negatively correlated with cytokine-induced signaling (such as IFNAR1, DDX58) and T1D susceptibility genes (IFIH1), whereas correlation of these genes with MAFB was weaker. In order to evaluate if the loss of MafA altered the immune status of islets, MafA deficient mouse islets (MafA−/−) were assessed for inherent anti-viral response and susceptibility to enterovirus infection. MafA deficient mouse islets had elevated basal levels of Ifnβ1, Rig1 (DDX58 in humans), and Mda5 (IFIH1) which resulted in reduced virus propagation in response to coxsackievirus B3 (CVB3) infection. Moreover, an acute knockdown of MafA in β-cell lines also enhanced Rig1 and Mda5 protein levels. Our results suggest that precise regulation of MAFA levels is critical for islet cell-specific cytokine production, which is a critical parameter for the inflammatory status of pancreatic islets.
Collapse
Affiliation(s)
- Tania Singh
- Stem Cell Center, Lund University, 22184, Lund, Sweden.
| | | | - Cheng Luan
- Lund University Diabetes Center, 22184, Lund, Sweden.
| | | | | | | | - Erik Renström
- Lund University Diabetes Center, 22184, Lund, Sweden.
| | - Shamit Soneji
- Stem Cell Center, Lund University, 22184, Lund, Sweden.
| | - Corrado Cilio
- Lund University Diabetes Center, 22184, Lund, Sweden.
| | - Isabella Artner
- Stem Cell Center, Lund University, 22184, Lund, Sweden.
- Lund University Diabetes Center, 22184, Lund, Sweden.
| |
Collapse
|
17
|
Shcherbina L, Lindqvist A, Thorén Fischer AH, Ahlqvist E, Zhang E, Falkmer SE, Renström E, Koffert J, Honka H, Wierup N. Intestinal CART is a regulator of GIP and GLP-1 secretion and expression. Mol Cell Endocrinol 2018; 476:8-16. [PMID: 29627317 DOI: 10.1016/j.mce.2018.04.002] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/10/2017] [Revised: 03/26/2018] [Accepted: 04/05/2018] [Indexed: 12/20/2022]
Abstract
Impaired incretin effect is a culprit in Type 2 Diabetes. Cocaine- and amphetamine-regulated transcript (CART) is a regulatory peptide controlling pancreatic islet hormone secretion and beta-cell survival. Here we studied the potential expression of CART in enteroendocrine cells and examined the role of CART as a regulator of incretin secretion and expression. CART expression was found in glucose-dependent insulinotropic polypeptide (GIP)-producing K-cells and glucagon-like peptide-1 (GLP-1)-producing L-cells in human duodenum and jejunum and circulating CART levels were increased 60 min after a meal in humans. CART expression was increased by fatty acids and GIP, but unaffected by glucose in GLUTag and STC-1 cells. Exogenous CART had no effect on GIP and GLP-1 expression and secretion in GLUTag or STC-1 cells, but siRNA-mediated silencing of CART reduced GLP-1 expression and secretion. Furthermore, acute intravenous administration of CART increased GIP and GLP-1 secretion during an oral glucose-tolerance test in mice. We conclude that CART is a novel constituent of human K- and L-cells with stimulatory actions on incretin secretion and that interfering with the CART system may be a therapeutic avenue for T2D.
Collapse
Affiliation(s)
| | - A Lindqvist
- Lund University Diabetes Centre, Malmö, Sweden
| | | | - E Ahlqvist
- Lund University Diabetes Centre, Malmö, Sweden
| | - E Zhang
- Lund University Diabetes Centre, Malmö, Sweden
| | - S E Falkmer
- Department of Clinical Pathology, Ryhov Hospital, Jönköping, Sweden
| | - E Renström
- Lund University Diabetes Centre, Malmö, Sweden
| | - J Koffert
- Turku PET Centre, University of Turku, Turku, Finland
| | - H Honka
- Turku PET Centre, University of Turku, Turku, Finland
| | - N Wierup
- Lund University Diabetes Centre, Malmö, Sweden.
| |
Collapse
|
18
|
Keller M, Dalla-Riva J, Kurbasic A, Al-Majdoub M, Spegel P, de Marinis Y, Wierup N, Ling C, Renström E, Hansson O, Mulder H, Franks PW. Genome editing (CRISPR-Cas9) to identify and characterise functional variants determining metformin response. DIABETOL STOFFWECHS 2018. [DOI: 10.1055/s-0038-1657798] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
Affiliation(s)
- M Keller
- Universität Leipzig, Leipzig, Germany
- Lund University, Department of Clinical Science, Clinical Research Centre, Skåne University Hospital, Malmö, Sweden
| | - J Dalla-Riva
- Lund University, Department of Clinical Science, Clinical Research Centre, Skåne University Hospital, Malmö, Sweden
| | - A Kurbasic
- Lund University, Department of Clinical Science, Clinical Research Centre, Skåne University Hospital, Malmö, Sweden
| | - M Al-Majdoub
- Lund University, Department of Clinical Science, Clinical Research Centre, Skåne University Hospital, Malmö, Sweden
| | - P Spegel
- Lund University, Department of Clinical Science, Clinical Research Centre, Skåne University Hospital, Malmö, Sweden
| | - Y de Marinis
- Lund University, Department of Clinical Science, Clinical Research Centre, Skåne University Hospital, Malmö, Sweden
| | - N Wierup
- Lund University, Department of Clinical Science, Clinical Research Centre, Skåne University Hospital, Malmö, Sweden
| | - C Ling
- Lund University, Department of Clinical Science, Clinical Research Centre, Skåne University Hospital, Malmö, Sweden
| | - E Renström
- Lund University, Department of Clinical Science, Clinical Research Centre, Skåne University Hospital, Malmö, Sweden
| | - O Hansson
- Lund University, Department of Clinical Science, Clinical Research Centre, Skåne University Hospital, Malmö, Sweden
| | - H Mulder
- Lund University, Department of Clinical Science, Clinical Research Centre, Skåne University Hospital, Malmö, Sweden
| | - PW Franks
- Lund University, Department of Clinical Science, Clinical Research Centre, Skåne University Hospital, Malmö, Sweden
- Umeå University, Department of Plublic Health and Clinical Medicine, Section for Medicine, Umeå, Sweden
- Harvard T.H. Chan School of Public Health, Department of Nutrition, Boston, United States
| |
Collapse
|
19
|
King BC, Golec E, Rosberg R, Zhang E, O’Connell D, Netanyah E, Halperin J, Renström E, Blom AM. A cryptic non-GPI anchored form of CD59 facilitates insulin secretion from pancreatic beta cells. Mol Immunol 2017. [DOI: 10.1016/j.molimm.2017.06.072] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
20
|
De Marinis Y, Sun J, Bompada P, Domènech Omella J, Luan C, Halu A, Renström E, Sharma A, Ridderstråle M. Regulation of Nuclear Receptor Interacting Protein 1 (NRIP1) Gene Expression in Response to Weight Loss and Exercise in Humans. Obesity (Silver Spring) 2017; 25:1400-1409. [PMID: 28656645 DOI: 10.1002/oby.21899] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/30/2016] [Revised: 04/20/2017] [Accepted: 05/11/2017] [Indexed: 01/12/2023]
Abstract
OBJECTIVE Nuclear receptor interacting protein 1 (NRIP1) is an important energy regulator, but few studies have addressed its role in humans. This study investigated adipose tissue and skeletal muscle NRIP1 gene expression and serum levels in response to weight loss and exercise in humans. METHODS NRIP1 expression was measured by microarray and serum NRIP1 by ELISA and Western blotting. Skeletal muscle transcriptomes were analyzed from Gene Expression Omnibus databases. Network-based proximity analysis was performed on the proximity of NRIP1 interacting genes in the human interactome. RESULTS In patients with obesity, adipose tissue NRIP1 mRNA expression increased during weight loss and weight maintenance and showed strong associations with metabolic markers and anthropometric parameters. Serum NRIP1 protein levels also increased after weight loss. In skeletal muscle, imposed rest increased NRIP1 expression by 80%, and strength training increased expression by ∼25% compared to baseline. Following rest, NRIP1 expression became sensitive to insulin stimulation. After re-training, NRIP1 expression decreased. Interactome analysis showed significant proximity of NRIP1 interacting partners to the obesity network/module. CONCLUSIONS NRIP1 gene expression and serum levels are strongly associated with metabolic states such as obesity, weight loss, different types of exercise, and peripheral tissue insulin resistance, potentially as a mediator of sedentary effects.
Collapse
Affiliation(s)
- Yang De Marinis
- Diabetes and Endocrinology, Lund University Diabetes Centre, Lund University, Malmö, Sweden
| | - Jiangming Sun
- Clinical Obesity Research, Lund University Diabetes Centre, Lund University, Malmö, Sweden
| | - Pradeep Bompada
- Diabetes and Endocrinology, Lund University Diabetes Centre, Lund University, Malmö, Sweden
| | - Judit Domènech Omella
- Diabetes and Endocrinology, Lund University Diabetes Centre, Lund University, Malmö, Sweden
| | - Cheng Luan
- Islet Pathophysiology, Department of Clinical Sciences, Lund University Diabetes Centre, Lund University, Malmö, Sweden
| | - Arda Halu
- Channing Division of Network Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA
| | - Erik Renström
- Islet Pathophysiology, Department of Clinical Sciences, Lund University Diabetes Centre, Lund University, Malmö, Sweden
| | - Amitabh Sharma
- Channing Division of Network Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA
- Center for Complex Network Research, Department of Physics, Northeastern University, Boston, Massachusetts, USA
- Center for Cancer Systems Biology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA
| | - Martin Ridderstråle
- Clinical Obesity Research, Lund University Diabetes Centre, Lund University, Malmö, Sweden
- Center for Interdisciplinary Cardiovascular Sciences, Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA
- Steno Diabetes Center A/S, Gentofte, Denmark
- Novo Nordisk A/S, Søborg, Denmark
| |
Collapse
|
21
|
Kulak K, Westermark GT, Papac-Milicevic N, Renström E, Blom AM, King BC. The human serum protein C4b-binding protein inhibits pancreatic IAPP-induced inflammasome activation. Diabetologia 2017; 60:1522-1533. [PMID: 28500395 PMCID: PMC5491568 DOI: 10.1007/s00125-017-4286-3] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/14/2016] [Accepted: 03/13/2017] [Indexed: 01/08/2023]
Abstract
AIMS/HYPOTHESIS Inflammasome activation and subsequent IL-1β production is a driver of islet pathology in type 2 diabetes. Oligomers, but not mature amyloid fibrils, of human islet amyloid polypeptide (IAPP), which is co-secreted with insulin, trigger NOD-like receptor pyrin domain containing-3 (NLRP3) inflammasome activation. C4b-binding protein (C4BP), present in serum, binds to IAPP and affects transition of IAPP monomers and oligomers to amyloid fibrils. We therefore hypothesised that C4BP inhibits IAPP-mediated inflammasome activation and IL-1β production. METHODS Macrophages were exposed to IAPP in the presence or absence of plasma-purified human C4BP, and inflammasome activation was assessed by IL-1β secretion as detected by ELISA and reporter cell lines. IAPP fibrillation was assessed by thioflavin T assay. Uptake of IAPP-C4BP complexes and their effects on phagolysosomal stability were assessed by flow cytometry and confocal microscopy. The effect of C4BP regulation of IAPP-mediated inflammasome activation on beta cell function was assessed using a clonal rat beta cell line. Immunohistochemistry was used to examine the association of IAPP amyloid deposits and macrophage infiltration in isolated human and mouse pancreatic islets, and expression of C4BP from isolated human pancreatic islets was assessed by quantitative PCR, immunohistochemistry and western blot. RESULTS C4BP significantly inhibited IAPP-mediated IL-1β secretion from primed macrophages at physiological concentrations in a dose-dependent manner. C4BP bound to and was internalised together with IAPP. C4BP did not affect IAPP uptake into phagolysosomal compartments, although it did inhibit its formation into amyloid fibrils. The loss of macrophage phagolysosomal integrity induced by IAPP incubation was inhibited by co-incubation with C4BP. Supernatant fractions from macrophages activated with IAPP inhibited both insulin secretion and viability of clonal beta cells in an IL-1β-dependent manner but the presence of C4BP during macrophage IAPP incubation rescued beta cell function and viability. In human and mouse islets, the presence of amyloid deposits correlated with higher numbers of infiltrating macrophages. Isolated human islets expressed and secreted C4BP, which increased with addition of IL-1β. CONCLUSIONS/INTERPRETATION IAPP deposition is associated with inflammatory cell infiltrates in pancreatic islets. C4BP blocks IAPP-induced inflammasome activation by preventing the loss of macrophage phagolysosomal integrity required for NLRP3 activation. The consequence of this is the preservation of beta cell function and viability. C4BP is secreted directly from human pancreatic islets and this increases in response to inflammatory cytokines. We therefore propose that C4BP acts as an extracellular chaperone protein that limits the proinflammatory effects of IAPP.
Collapse
Affiliation(s)
- Klaudia Kulak
- Division of Medical Protein Chemistry, Department of Translational Medicine, Lund University, Inga Marie Nilssons Gata 53, Skåne University Hospital, S20502, Malmö, Sweden
| | | | | | - Erik Renström
- Department of Clinical Sciences Malmö, Lund University Diabetes Centre, Lund University, Malmö, Sweden
| | - Anna M Blom
- Division of Medical Protein Chemistry, Department of Translational Medicine, Lund University, Inga Marie Nilssons Gata 53, Skåne University Hospital, S20502, Malmö, Sweden
| | - Ben C King
- Division of Medical Protein Chemistry, Department of Translational Medicine, Lund University, Inga Marie Nilssons Gata 53, Skåne University Hospital, S20502, Malmö, Sweden.
| |
Collapse
|
22
|
Kazim AS, Storm P, Zhang E, Renström E. Palmitoylation of Ca 2+ channel subunit Ca Vβ 2a induces pancreatic beta-cell toxicity via Ca 2+ overload. Biochem Biophys Res Commun 2017; 491:740-746. [PMID: 28739256 DOI: 10.1016/j.bbrc.2017.07.117] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/29/2017] [Accepted: 07/20/2017] [Indexed: 11/28/2022]
Abstract
High blood glucose triggers the release of insulin from pancreatic beta cells, but if chronic, causes cellular stress, partly due to impaired Ca2+ homeostasis. Ca2+ influx is controlled by voltage-gated calcium channels (CaV) and high density of CaV in the plasma membrane could lead to Ca2+ overload. Trafficking of the pore-forming CaVα1 subunit to the plasma membrane is regulated by auxiliary subunits, such as the CaVβ2a subunit. This study investigates, using Ca2+ imaging and immunohistochemistry, the role of palmitoylation of CaVβ2a in maintaining Ca2+ homeostasis and beta cell function. RNA sequencing data showed that gene expression of human CACNB2, in particular CACNB2A (CaVβ2a), is highest in islets when compared to other tissues. Since CaVβ2a can be regulated through palmitoylation of its two cysteines, CaVβ2a and its mutant form were overexpressed in pancreatic beta cells. Palmitoylated CaVβ2a tethered to the plasma membrane and colocalized with CaV1.2 while the mutant form remained in the cytosol. Interestingly, CaVβ2a overexpression raised basal intracellular Ca2+ and increased beta cell apoptosis. Our study shows that palmitoylation of CaVβ2a is necessary for CaVα1 trafficking to the plasma membrane. However, excessive number of palmitoylated CaVβ2a leads to Ca2+ overload and beta cell death.
Collapse
Affiliation(s)
- Abdulla S Kazim
- Lund University Diabetes Centre, Department of Clinical Sciences Malmö, Lund University, SE 20502, Malmö, Sweden
| | - Petter Storm
- Lund University Diabetes Centre, Department of Clinical Sciences Malmö, Lund University, SE 20502, Malmö, Sweden
| | - Enming Zhang
- Lund University Diabetes Centre, Department of Clinical Sciences Malmö, Lund University, SE 20502, Malmö, Sweden.
| | - Erik Renström
- Lund University Diabetes Centre, Department of Clinical Sciences Malmö, Lund University, SE 20502, Malmö, Sweden.
| |
Collapse
|
23
|
Mastrolia V, Flucher SM, Obermair GJ, Drach M, Hofer H, Renström E, Schwartz A, Striessnig J, Flucher BE, Tuluc P. Loss of α 2δ-1 Calcium Channel Subunit Function Increases the Susceptibility for Diabetes. Diabetes 2017; 66:897-907. [PMID: 28115397 PMCID: PMC7360433 DOI: 10.2337/db16-0336] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/14/2016] [Accepted: 01/18/2017] [Indexed: 11/13/2022]
Abstract
Reduced pancreatic β-cell function or mass is the critical problem in developing diabetes. Insulin release from β-cells depends on Ca2+ influx through high voltage-gated Ca2+ channels (HVCCs). Ca2+ influx also regulates insulin synthesis and insulin granule priming and contributes to β-cell electrical activity. The HVCCs are multisubunit protein complexes composed of a pore-forming α1 and auxiliary β and α2δ subunits. α2δ is a key regulator of membrane incorporation and function of HVCCs. Here we show that genetic deletion of α2δ-1, the dominant α2δ subunit in pancreatic islets, results in glucose intolerance and diabetes without affecting insulin sensitivity. Lack of the α2δ-1 subunit reduces the Ca2+ currents through all HVCC isoforms expressed in β-cells equally in male and female mice. The reduced Ca2+ influx alters the kinetics and amplitude of the global Ca2+ response to glucose in pancreatic islets and significantly reduces insulin release in both sexes. The progression of diabetes in males is aggravated by a selective loss of β-cell mass, while a stronger basal insulin release alleviates the diabetes symptoms in most α2δ-1-/- female mice. Together, these findings demonstrate that the loss of the Ca2+ channel α2δ-1 subunit function increases the susceptibility for developing diabetes in a sex-dependent manner.
Collapse
Affiliation(s)
- Vincenzo Mastrolia
- Department of Physiology and Medical Physics, Medical University Innsbruck, Innsbruck, Austria
- Department of Pharmacology and Toxicology, Institute of Pharmacy, University of Innsbruck, Innsbruck, Austria
| | - Sylvia M Flucher
- Department of Physiology and Medical Physics, Medical University Innsbruck, Innsbruck, Austria
| | - Gerald J Obermair
- Department of Physiology and Medical Physics, Medical University Innsbruck, Innsbruck, Austria
| | - Mathias Drach
- Department of General Pathology, Medical University Innsbruck, Innsbruck, Austria
| | - Helene Hofer
- Department of Physiology and Medical Physics, Medical University Innsbruck, Innsbruck, Austria
| | - Erik Renström
- Department of Clinical Sciences Malmö, Lund University, Lund, Sweden
| | - Arnold Schwartz
- College of Medicine, University of Cincinnati, Cincinnati, OH
| | - Jörg Striessnig
- Department of Pharmacology and Toxicology, Institute of Pharmacy, University of Innsbruck, Innsbruck, Austria
| | - Bernhard E Flucher
- Department of Physiology and Medical Physics, Medical University Innsbruck, Innsbruck, Austria
| | - Petronel Tuluc
- Department of Physiology and Medical Physics, Medical University Innsbruck, Innsbruck, Austria
- Department of Pharmacology and Toxicology, Institute of Pharmacy, University of Innsbruck, Innsbruck, Austria
| |
Collapse
|
24
|
King BC, Golec E, Zhang E, O’Connell D, Netanyah E, Rosberg R, Halperin J, Renström E, Blom AM. A cryptic non-GPI anchored form of CD59 facilitates insulin secretion from pancreatic beta cells. Immunobiology 2016. [DOI: 10.1016/j.imbio.2016.06.093] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
25
|
Abels M, Riva M, Bennet H, Ahlqvist E, Dyachok O, Nagaraj V, Shcherbina L, Fred RG, Poon W, Sörhede-Winzell M, Fadista J, Lindqvist A, Kask L, Sathanoori R, Dekker-Nitert M, Kuhar MJ, Ahrén B, Wollheim CB, Hansson O, Tengholm A, Fex M, Renström E, Groop L, Lyssenko V, Wierup N. CART is overexpressed in human type 2 diabetic islets and inhibits glucagon secretion and increases insulin secretion. Diabetologia 2016; 59:1928-37. [PMID: 27338624 DOI: 10.1007/s00125-016-4020-6] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/17/2016] [Accepted: 05/23/2016] [Indexed: 11/30/2022]
Abstract
AIMS/HYPOTHESIS Insufficient insulin release and hyperglucagonaemia are culprits in type 2 diabetes. Cocaine- and amphetamine-regulated transcript (CART, encoded by Cartpt) affects islet hormone secretion and beta cell survival in vitro in rats, and Cart (-/-) mice have diminished insulin secretion. We aimed to test if CART is differentially regulated in human type 2 diabetic islets and if CART affects insulin and glucagon secretion in vitro in humans and in vivo in mice. METHODS CART expression was assessed in human type 2 diabetic and non-diabetic control pancreases and rodent models of diabetes. Insulin and glucagon secretion was examined in isolated islets and in vivo in mice. Ca(2+) oscillation patterns and exocytosis were studied in mouse islets. RESULTS We report an important role of CART in human islet function and glucose homeostasis in mice. CART was found to be expressed in human alpha and beta cells and in a subpopulation of mouse beta cells. Notably, CART expression was several fold higher in islets of type 2 diabetic humans and rodents. CART increased insulin secretion in vivo in mice and in human and mouse islets. Furthermore, CART increased beta cell exocytosis, altered the glucose-induced Ca(2+) signalling pattern in mouse islets from fast to slow oscillations and improved synchronisation of the oscillations between different islet regions. Finally, CART reduced glucagon secretion in human and mouse islets, as well as in vivo in mice via diminished alpha cell exocytosis. CONCLUSIONS/INTERPRETATION We conclude that CART is a regulator of glucose homeostasis and could play an important role in the pathophysiology of type 2 diabetes. Based on the ability of CART to increase insulin secretion and reduce glucagon secretion, CART-based agents could be a therapeutic modality in type 2 diabetes.
Collapse
Affiliation(s)
- Mia Abels
- Lund University Diabetes Centre, Skåne University Hospital, Lund and Malmö, Sweden
| | - Matteo Riva
- Lund University Diabetes Centre, Skåne University Hospital, Lund and Malmö, Sweden
| | - Hedvig Bennet
- Lund University Diabetes Centre, Skåne University Hospital, Lund and Malmö, Sweden
| | - Emma Ahlqvist
- Lund University Diabetes Centre, Skåne University Hospital, Lund and Malmö, Sweden
| | - Oleg Dyachok
- Department of Medical Cell Biology, Uppsala University Biomedical Centre, Uppsala, Sweden
| | - Vini Nagaraj
- Lund University Diabetes Centre, Skåne University Hospital, Lund and Malmö, Sweden
| | - Liliya Shcherbina
- Lund University Diabetes Centre, Skåne University Hospital, Lund and Malmö, Sweden
| | - Rikard G Fred
- Lund University Diabetes Centre, Skåne University Hospital, Lund and Malmö, Sweden
| | - Wenny Poon
- Lund University Diabetes Centre, Skåne University Hospital, Lund and Malmö, Sweden
| | | | - Joao Fadista
- Lund University Diabetes Centre, Skåne University Hospital, Lund and Malmö, Sweden
| | - Andreas Lindqvist
- Lund University Diabetes Centre, Skåne University Hospital, Lund and Malmö, Sweden
| | - Lena Kask
- Lund University Diabetes Centre, Skåne University Hospital, Lund and Malmö, Sweden
| | - Ramasri Sathanoori
- Lund University Diabetes Centre, Skåne University Hospital, Lund and Malmö, Sweden
| | | | - Michael J Kuhar
- The Yerkes Research Center of Emory University, Atlanta, GA, USA
| | - Bo Ahrén
- Lund University Diabetes Centre, Skåne University Hospital, Lund and Malmö, Sweden
| | - Claes B Wollheim
- Department of Cell Physiology and Metabolism, University Medical Centre, Geneva, Switzerland
| | - Ola Hansson
- Lund University Diabetes Centre, Skåne University Hospital, Lund and Malmö, Sweden
| | - Anders Tengholm
- Department of Medical Cell Biology, Uppsala University Biomedical Centre, Uppsala, Sweden
| | - Malin Fex
- Lund University Diabetes Centre, Skåne University Hospital, Lund and Malmö, Sweden
| | - Erik Renström
- Lund University Diabetes Centre, Skåne University Hospital, Lund and Malmö, Sweden
| | - Leif Groop
- Lund University Diabetes Centre, Skåne University Hospital, Lund and Malmö, Sweden
| | - Valeriya Lyssenko
- Lund University Diabetes Centre, Skåne University Hospital, Lund and Malmö, Sweden
- Steno Diabetes Center A/S, Gentofte, Denmark
| | - Nils Wierup
- Lund University Diabetes Centre, Skåne University Hospital, Lund and Malmö, Sweden.
- Lund University Diabetes Centre, Skåne University Hospital, Department of Clinical Sciences in Malmö, Unit of Neuroendocrine Cell Biology, Lund University, Clinical Research Centre 91:12, Jan Waldenströms gata 35, 20502, Malmö, Sweden.
| |
Collapse
|
26
|
Sjölander J, Byman E, Kulak K, Nilsson SC, Zhang E, Krus U, Westermark GT, Storm P, King BC, Renström E, Blom AM. C4b-binding Protein Protects β-Cells from Islet Amyloid Polypeptide-induced Cytotoxicity. J Biol Chem 2016; 291:21644-21655. [PMID: 27566545 DOI: 10.1074/jbc.m116.731141] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/05/2016] [Revised: 08/15/2016] [Indexed: 12/21/2022] Open
Abstract
C4BP (C4b-binding protein) is a polymer of seven identical α chains and one unique β chain synthesized in liver and pancreas. We showed previously that C4BP enhances islet amyloid polypeptide (IAPP) fibril formation in vitro Now we report that polymeric C4BP strongly inhibited lysis of human erythrocytes incubated with monomeric IAPP, whereas no lysis was observed after incubation with preformed IAPP fibrils. In contrast, incubation with the monomeric α-chain of C4BP was less effective. These data indicate that polymeric C4BP with multiple binding sites for IAPP neutralizes lytic activity of IAPP. Furthermore, addition of monomeric IAPP to a rat insulinoma cell line (INS-1) resulted in decreased cell viability, which was restored in the presence of physiological concentrations of C4BP. Treatment of INS-1 cells and primary rat islets with IAPP also diminished their ability to secrete insulin upon stimulation with glucose, which was reversed in the presence of C4BP. Further, C4BP was internalized together with IAPP into INS-1 cells. Pathway analyses of mRNA expression microarray data indicated that cells exposed to C4BP and IAPP in comparison with IAPP alone increased expression of genes involved in cholesterol synthesis. Depletion of cholesterol through methyl-β-cyclodextrin or cholesterol oxidase abolished the protective effect of C4BP on IAPP cytotoxicity of INS-1 cells. Also, inhibition of phosphoinositide 3-kinase but not NF-κB had a similar effect. Taken together, C4BP protects β-cells from IAPP cytotoxicity by modulating IAPP fibril formation extracellularly and also, after uptake by the cells, by enhancing cholesterol synthesis.
Collapse
Affiliation(s)
| | - Elin Byman
- From the Departments of Translational Medicine and
| | | | | | - Enming Zhang
- Clinical Sciences, Lund University, S-20502 Malmö, Sweden and
| | - Ulrika Krus
- Clinical Sciences, Lund University, S-20502 Malmö, Sweden and
| | - Gunilla T Westermark
- the Department of Medical Cell Biology, Uppsala University, S-75123 Uppsala, Sweden
| | - Petter Storm
- Clinical Sciences, Lund University, S-20502 Malmö, Sweden and
| | - Ben C King
- From the Departments of Translational Medicine and
| | - Erik Renström
- Clinical Sciences, Lund University, S-20502 Malmö, Sweden and
| | - Anna M Blom
- From the Departments of Translational Medicine and
| |
Collapse
|
27
|
Nagaraj V, Kazim AS, Helgeson J, Lewold C, Barik S, Buda P, Reinbothe TM, Wennmalm S, Zhang E, Renström E. Elevated Basal Insulin Secretion in Type 2 Diabetes Caused by Reduced Plasma Membrane Cholesterol. Mol Endocrinol 2016; 30:1059-1069. [PMID: 27533789 PMCID: PMC5045496 DOI: 10.1210/me.2016-1023] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022] Open
Abstract
Elevated basal insulin secretion under fasting conditions together with insufficient stimulated insulin release is an important hallmark of type 2 diabetes, but the mechanisms controlling basal insulin secretion remain unclear. Membrane rafts exist in pancreatic islet cells and spatially organize membrane ion channels and proteins controlling exocytosis, which may contribute to the regulation of insulin secretion. Membrane rafts (cholesterol and sphingolipid containing microdomains) were dramatically reduced in human type 2 diabetic and diabetic Goto-Kakizaki (GK) rat islets when compared with healthy islets. Oxidation of membrane cholesterol markedly reduced microdomain staining intensity in healthy human islets, but was without effect in type 2 diabetic islets. Intriguingly, oxidation of cholesterol affected glucose-stimulated insulin secretion only modestly, whereas basal insulin release was elevated. This was accompanied by increased intracellular Ca2+ spike frequency and Ca2+ influx and explained by enhanced single Ca2+ channel activity. These results suggest that the reduced presence of membrane rafts could contribute to the elevated basal insulin secretion seen in type 2 diabetes.
Collapse
Affiliation(s)
- Vini Nagaraj
- Department of Clinical Sciences Malmö (V.N., A.S.K., J.H., C.L., S.B., P.B., T.M.R., E.Z., E.R.), Lund University Diabetes Centre, Lund University, SE-20502 Malmö, Sweden; and Science for Life Laboratory (S.W.), KTH Royal Institute of Technology, SE-171 77 Stockholm, Sweden
| | - Abdulla S Kazim
- Department of Clinical Sciences Malmö (V.N., A.S.K., J.H., C.L., S.B., P.B., T.M.R., E.Z., E.R.), Lund University Diabetes Centre, Lund University, SE-20502 Malmö, Sweden; and Science for Life Laboratory (S.W.), KTH Royal Institute of Technology, SE-171 77 Stockholm, Sweden
| | - Johan Helgeson
- Department of Clinical Sciences Malmö (V.N., A.S.K., J.H., C.L., S.B., P.B., T.M.R., E.Z., E.R.), Lund University Diabetes Centre, Lund University, SE-20502 Malmö, Sweden; and Science for Life Laboratory (S.W.), KTH Royal Institute of Technology, SE-171 77 Stockholm, Sweden
| | - Clemens Lewold
- Department of Clinical Sciences Malmö (V.N., A.S.K., J.H., C.L., S.B., P.B., T.M.R., E.Z., E.R.), Lund University Diabetes Centre, Lund University, SE-20502 Malmö, Sweden; and Science for Life Laboratory (S.W.), KTH Royal Institute of Technology, SE-171 77 Stockholm, Sweden
| | - Satadal Barik
- Department of Clinical Sciences Malmö (V.N., A.S.K., J.H., C.L., S.B., P.B., T.M.R., E.Z., E.R.), Lund University Diabetes Centre, Lund University, SE-20502 Malmö, Sweden; and Science for Life Laboratory (S.W.), KTH Royal Institute of Technology, SE-171 77 Stockholm, Sweden
| | - Pawel Buda
- Department of Clinical Sciences Malmö (V.N., A.S.K., J.H., C.L., S.B., P.B., T.M.R., E.Z., E.R.), Lund University Diabetes Centre, Lund University, SE-20502 Malmö, Sweden; and Science for Life Laboratory (S.W.), KTH Royal Institute of Technology, SE-171 77 Stockholm, Sweden
| | - Thomas M Reinbothe
- Department of Clinical Sciences Malmö (V.N., A.S.K., J.H., C.L., S.B., P.B., T.M.R., E.Z., E.R.), Lund University Diabetes Centre, Lund University, SE-20502 Malmö, Sweden; and Science for Life Laboratory (S.W.), KTH Royal Institute of Technology, SE-171 77 Stockholm, Sweden
| | - Stefan Wennmalm
- Department of Clinical Sciences Malmö (V.N., A.S.K., J.H., C.L., S.B., P.B., T.M.R., E.Z., E.R.), Lund University Diabetes Centre, Lund University, SE-20502 Malmö, Sweden; and Science for Life Laboratory (S.W.), KTH Royal Institute of Technology, SE-171 77 Stockholm, Sweden
| | - Enming Zhang
- Department of Clinical Sciences Malmö (V.N., A.S.K., J.H., C.L., S.B., P.B., T.M.R., E.Z., E.R.), Lund University Diabetes Centre, Lund University, SE-20502 Malmö, Sweden; and Science for Life Laboratory (S.W.), KTH Royal Institute of Technology, SE-171 77 Stockholm, Sweden
| | - Erik Renström
- Department of Clinical Sciences Malmö (V.N., A.S.K., J.H., C.L., S.B., P.B., T.M.R., E.Z., E.R.), Lund University Diabetes Centre, Lund University, SE-20502 Malmö, Sweden; and Science for Life Laboratory (S.W.), KTH Royal Institute of Technology, SE-171 77 Stockholm, Sweden
| |
Collapse
|
28
|
Zhou Y, Oskolkov N, Shcherbina L, Ratti J, Kock KH, Su J, Martin B, Oskolkova MZ, Göransson O, Bacon J, Li W, Bucciarelli S, Cilio C, Brazma A, Thatcher B, Rung J, Wierup N, Renström E, Groop L, Hansson O. HMGB1 binds to the rs7903146 locus in TCF7L2 in human pancreatic islets. Mol Cell Endocrinol 2016; 430:138-45. [PMID: 26845344 DOI: 10.1016/j.mce.2016.01.027] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/02/2015] [Revised: 01/19/2016] [Accepted: 01/28/2016] [Indexed: 02/03/2023]
Abstract
The intronic SNP rs7903146 in the T-cell factor 7-like 2 gene (TCF7L2) is the common genetic variant most highly associated with Type 2 diabetes known to date. The risk T-allele is located in an open chromatin region specific to human pancreatic islets of Langerhans, thereby accessible for binding of regulatory proteins. The risk T-allele locus exhibits stronger enhancer activity compared to the non-risk C-allele. The aim of this study was to identify transcriptional regulators that bind the open chromatin region in the rs7903146 locus and thereby potentially regulate TCF7L2 expression and activity. Using affinity chromatography followed by Edman sequencing, we identified one candidate regulatory protein, i.e. high-mobility group protein B1 (HMGB1). The binding of HMGB1 to the rs7903146 locus was confirmed in pancreatic islets from human deceased donors, in HCT116 and in HEK293 cell lines using: (i) protein purification on affinity columns followed by Western blot, (ii) chromatin immunoprecipitation followed by qPCR and (iii) electrophoretic mobility shift assay. The results also suggested that HMGB1 might have higher binding affinity to the C-allele of rs7903146 compared to the T-allele, which was supported in vitro using Dynamic Light Scattering, possibly in a tissue-specific manner. The functional consequence of HMGB1 depletion in HCT116 and INS1 cells was reduced insulin and TCF7L2 mRNA expression, TCF7L2 transcriptional activity and glucose stimulated insulin secretion. These findings suggest that the rs7903146 locus might exert its enhancer function by interacting with HMGB1 in an allele dependent manner.
Collapse
Affiliation(s)
- Yuedan Zhou
- Department of Clinical Sciences, CRC, Lund University, Malmö, 20502, Sweden
| | - Nikolay Oskolkov
- Department of Clinical Sciences, CRC, Lund University, Malmö, 20502, Sweden
| | - Liliya Shcherbina
- Department of Clinical Sciences, CRC, Lund University, Malmö, 20502, Sweden
| | - Joyce Ratti
- Department of Biochemistry, University of Cambridge, CB2 1GA, Cambridge, UK
| | - Kian-Hong Kock
- Department of Biochemistry, University of Cambridge, CB2 1GA, Cambridge, UK
| | - Jing Su
- European Bioinformatics Institute, Functional Genomics, Hinxton, Cambridge CB10 1SD, UK
| | - Brian Martin
- National Institute of Mental Health NIMH, National Institutes of Health, Bethesda, MD 20892, USA
| | | | - Olga Göransson
- Department of Clinical Sciences, CRC, Lund University, Malmö, 20502, Sweden
| | - Julie Bacon
- Department of Clinical Sciences, CRC, Lund University, Malmö, 20502, Sweden
| | - Weimin Li
- Department of Physical Chemistry, Lund University, Lund, 22100, Sweden
| | | | - Corrado Cilio
- Department of Clinical Sciences, CRC, Lund University, Malmö, 20502, Sweden
| | - Alvis Brazma
- European Bioinformatics Institute, Functional Genomics, Hinxton, Cambridge CB10 1SD, UK
| | - Bradley Thatcher
- Department of Clinical Sciences, CRC, Lund University, Malmö, 20502, Sweden
| | - Johan Rung
- European Bioinformatics Institute, Functional Genomics, Hinxton, Cambridge CB10 1SD, UK
| | - Nils Wierup
- Department of Clinical Sciences, CRC, Lund University, Malmö, 20502, Sweden
| | - Erik Renström
- Department of Clinical Sciences, CRC, Lund University, Malmö, 20502, Sweden
| | - Leif Groop
- Department of Clinical Sciences, CRC, Lund University, Malmö, 20502, Sweden
| | - Ola Hansson
- Department of Clinical Sciences, CRC, Lund University, Malmö, 20502, Sweden.
| |
Collapse
|
29
|
Tang Y, Axelsson AS, Spégel P, Andersson LE, Mulder H, Groop LC, Renström E, Rosengren AH. Genotype-based treatment of type 2 diabetes with an α2A-adrenergic receptor antagonist. Sci Transl Med 2016; 6:257ra139. [PMID: 25298321 DOI: 10.1126/scitranslmed.3009934] [Citation(s) in RCA: 49] [Impact Index Per Article: 6.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
The feasibility of exploiting genomic information for individualized treatment of polygenic diseases remains uncertain. A genetic variant in ADRA2A, which encodes the α(2A)-adrenergic receptor (α(2A)AR), was recently associated with type 2 diabetes. This variant causes receptor overexpression and impaired insulin secretion; thus, we hypothesized that blocking α(2A)AR pharmacologically could improve insulin secretion in patients with the risk genotype. A total of 50 type 2 diabetes patients were recruited on the basis of ADRA2A genotype for a randomized placebo-controlled intervention study with the α(2A)AR antagonist yohimbine. The patients received 0, 10, or 20 mg of yohimbine at three separate visits. The primary endpoint was insulin secretion at 30 min (Ins30) during an oral glucose tolerance test (OGTT). Patients with the risk variant had 25% lower Ins30 than those without risk genotype. After administration of 20 mg of yohimbine, Ins30 was enhanced by 29% in the risk group, making secretion similar to patients carrying the low-risk allele. The corrected insulin response and disposition index in individuals with the high-risk (but not low-risk) allele were improved by 59 ± 18% and 43 ± 14%, respectively. The beneficial effect of yohimbine was not a consequence of improved insulin sensitivity. In summary, the data show that the insulin secretion defect in patients carrying the ADRA2A risk genotype can be corrected by α(2A)AR antagonism. The findings show that knowledge of genetic risk variants can be used to guide therapeutic interventions that directly target the underlying pathophysiology and demonstrate the potential of individualized genotype-specific treatment of type 2 diabetes.
Collapse
Affiliation(s)
- Yunzhao Tang
- Department of Clinical Sciences, Lund University, SE-20502 Malmö, Sweden. 2011 Collaborative Innovation Center of Tianjin for Medical Epigenetics (Ministry of Health), Key Laboratory of Hormones and Development, Metabolic Diseases Hospital & Tianjin Institute of Endocrinology, Tianjin Medical University, Tianjin 300070, China
| | - Annika S Axelsson
- Department of Clinical Sciences, Lund University, SE-20502 Malmö, Sweden
| | - Peter Spégel
- Department of Clinical Sciences, Lund University, SE-20502 Malmö, Sweden
| | - Lotta E Andersson
- Department of Clinical Sciences, Lund University, SE-20502 Malmö, Sweden
| | - Hindrik Mulder
- Department of Clinical Sciences, Lund University, SE-20502 Malmö, Sweden
| | - Leif C Groop
- Department of Clinical Sciences, Lund University, SE-20502 Malmö, Sweden
| | - Erik Renström
- Department of Clinical Sciences, Lund University, SE-20502 Malmö, Sweden
| | - Anders H Rosengren
- Department of Clinical Sciences, Lund University, SE-20502 Malmö, Sweden.
| |
Collapse
|
30
|
Ganic E, Singh T, Luan C, Fadista J, Johansson JK, Cyphert HA, Bennet H, Storm P, Prost G, Ahlenius H, Renström E, Stein R, Groop L, Fex M, Artner I. MafA-Controlled Nicotinic Receptor Expression Is Essential for Insulin Secretion and Is Impaired in Patients with Type 2 Diabetes. Cell Rep 2016; 14:1991-2002. [PMID: 26904947 PMCID: PMC5918632 DOI: 10.1016/j.celrep.2016.02.002] [Citation(s) in RCA: 24] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/29/2015] [Revised: 12/18/2015] [Accepted: 01/22/2016] [Indexed: 11/23/2022] Open
Abstract
Monoamine and acetylcholine neurotransmitters from the autonomic nervous system (ANS) regulate insulin secretion in pancreatic islets. The molecular mechanisms controlling neurotransmitter signaling in islet β cells and their impact on diabetes development are only partially understood. Using a glucose-intolerant, MafA-deficient mouse model, we demonstrate that MAFA controls ANS-mediated insulin secretion by activating the transcription of nicotinic (ChrnB2 and ChrnB4) and adrenergic (Adra2A) receptor genes, which are integral parts of acetylcholine-and monoamine-signaling pathways. We show that acetylcholine-mediated insulin secretion requires nicotinic signaling and that nicotinic receptor expression is positively correlated with insulin secretion and glycemic control in human donor islets. Moreover, polymorphisms spanning MAFA-binding regions within the human CHRNB4 gene are associated with type 2 diabetes. Our data show that MAFA transcriptional activity is required for establishing β cell sensitivity to neurotransmitter signaling and identify nicotinic signaling as a modulator of insulin secretion impaired in type 2 diabetes.
Collapse
MESH Headings
- Animals
- Autonomic Nervous System/metabolism
- Binding Sites
- Diabetes Mellitus, Experimental/genetics
- Diabetes Mellitus, Experimental/metabolism
- Diabetes Mellitus, Experimental/pathology
- Diabetes Mellitus, Type 2/genetics
- Diabetes Mellitus, Type 2/metabolism
- Diabetes Mellitus, Type 2/pathology
- Female
- Gene Expression Regulation
- Glucose Tolerance Test
- Humans
- Insulin/genetics
- Insulin/metabolism
- Insulin-Secreting Cells/metabolism
- Insulin-Secreting Cells/pathology
- Maf Transcription Factors, Large/genetics
- Maf Transcription Factors, Large/metabolism
- Mice
- Mice, Knockout
- Nerve Tissue Proteins/genetics
- Nerve Tissue Proteins/metabolism
- Polymorphism, Genetic
- Protein Binding
- Receptors, Adrenergic, alpha-2/genetics
- Receptors, Adrenergic, alpha-2/metabolism
- Receptors, Nicotinic/genetics
- Receptors, Nicotinic/metabolism
- Signal Transduction
- Transcription, Genetic
Collapse
Affiliation(s)
- Elvira Ganic
- Stem Cell Center, Lund University, Klinikgatan 26, Lund 22184, Sweden; Lund University Diabetes Center, Lund University, Klinikgatan 26, Lund 22184, Sweden
| | - Tania Singh
- Stem Cell Center, Lund University, Klinikgatan 26, Lund 22184, Sweden; Lund University Diabetes Center, Lund University, Klinikgatan 26, Lund 22184, Sweden
| | - Cheng Luan
- Lund University Diabetes Center, Lund University, Klinikgatan 26, Lund 22184, Sweden
| | - João Fadista
- Lund University Diabetes Center, Lund University, Klinikgatan 26, Lund 22184, Sweden
| | - Jenny K Johansson
- Stem Cell Center, Lund University, Klinikgatan 26, Lund 22184, Sweden; Lund University Diabetes Center, Lund University, Klinikgatan 26, Lund 22184, Sweden
| | - Holly Ann Cyphert
- Department of Molecular Physiology and Biophysics, Vanderbilt University Medical Center, Nashville, TN 37232, USA
| | - Hedvig Bennet
- Lund University Diabetes Center, Lund University, Klinikgatan 26, Lund 22184, Sweden
| | - Petter Storm
- Lund University Diabetes Center, Lund University, Klinikgatan 26, Lund 22184, Sweden
| | - Gaëlle Prost
- Stem Cell Center, Lund University, Klinikgatan 26, Lund 22184, Sweden
| | - Henrik Ahlenius
- Stem Cell Center, Lund University, Klinikgatan 26, Lund 22184, Sweden
| | - Erik Renström
- Lund University Diabetes Center, Lund University, Klinikgatan 26, Lund 22184, Sweden
| | - Roland Stein
- Department of Molecular Physiology and Biophysics, Vanderbilt University Medical Center, Nashville, TN 37232, USA
| | - Leif Groop
- Lund University Diabetes Center, Lund University, Klinikgatan 26, Lund 22184, Sweden
| | - Malin Fex
- Lund University Diabetes Center, Lund University, Klinikgatan 26, Lund 22184, Sweden
| | - Isabella Artner
- Stem Cell Center, Lund University, Klinikgatan 26, Lund 22184, Sweden; Lund University Diabetes Center, Lund University, Klinikgatan 26, Lund 22184, Sweden.
| |
Collapse
|
31
|
Merza M, Hartman H, Rahman M, Hwaiz R, Zhang E, Renström E, Luo L, Mörgelin M, Regner S, Thorlacius H. Neutrophil Extracellular Traps Induce Trypsin Activation, Inflammation, and Tissue Damage in Mice With Severe Acute Pancreatitis. Gastroenterology 2015; 149:1920-1931.e8. [PMID: 26302488 DOI: 10.1053/j.gastro.2015.08.026] [Citation(s) in RCA: 171] [Impact Index Per Article: 19.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/29/2015] [Revised: 08/13/2015] [Accepted: 08/15/2015] [Indexed: 12/14/2022]
Abstract
BACKGROUND & AIMS Neutrophils are involved in the development of acute pancreatitis (AP), but it is not clear how neutrophil-induced tissue damage is regulated. In addition to secreting antimicrobial compounds, activated neutrophils eliminate invading microorganisms by expelling nuclear DNA and histones to form extracellular web-like structures called neutrophil extracellular traps (NETs). However, NETs have been reported to contribute to organ dysfunction in patients with infectious diseases. We investigated whether NETs contribute to the development of AP in mice. METHODS AP was induced in C57BL/6 mice by infusion of taurocholate into the pancreatic duct or by intraperitoneal administration of L-arginine. Pancreata were collected and extracellular DNA was detected by Sytox green staining, levels of CXC chemokines, histones, and cytokines also were measured. Cell-free DNA was quantified in plasma samples. Signal transducer and activator of transcription 3 phosphorylation and trypsin activation were analyzed in isolated acinar cells. NETs were depleted by administration of DNase I to mice. Plasma was obtained from healthy individuals (controls) and patients with severe AP. RESULTS Infusion of taurocholate induced formation of NETs in pancreatic tissues of mice and increased levels of cell-free DNA in plasma. Neutrophil depletion prevented taurocholate-induced deposition of NETs in the pancreas. Administration of DNase I to mice reduced neutrophil infiltration and tissue damage in the inflamed pancreas and lung, and decreased levels of blood amylase, macrophage inflammatory protein-2, interleukin 6, and high-mobility groups protein 1. In mice given taurocholate, DNase I administration also reduced expression of integrin α M (macrophage-1 antigen) on circulating neutrophils. Similar results occurred in mice with L-arginine-induced AP. Addition of NETs and histones to acinar cells induced formation of trypsin and activation of signal transducer and activator of transcription 3; these processes were blocked by polysialic acid. Patients with severe AP had increased plasma levels of NET components compared with controls. CONCLUSIONS NETs form in the pancreata of mice during the development of AP, and NET levels are increased in plasma from patients with AP, compared with controls. NETs regulate organ inflammation and injury in mice with AP, and might be targeted to reduce pancreatic tissue damage and inflammation in patients.
Collapse
Affiliation(s)
- Mohammed Merza
- Section of Surgery, Department of Clinical Sciences, Malmö, Sweden
| | - Hannes Hartman
- Section of Surgery, Department of Clinical Sciences, Malmö, Sweden
| | - Milladur Rahman
- Section of Surgery, Department of Clinical Sciences, Malmö, Sweden
| | - Rundk Hwaiz
- Section of Surgery, Department of Clinical Sciences, Malmö, Sweden
| | - Enming Zhang
- Section of Islet Pathophysiology, Department of Clinical Sciences, Malmö, Sweden
| | - Erik Renström
- Section of Islet Pathophysiology, Department of Clinical Sciences, Malmö, Sweden
| | - Lingtao Luo
- Section of Surgery, Department of Clinical Sciences, Malmö, Sweden
| | - Matthias Mörgelin
- Division of Infection Medicine, Department of Clinical Sciences, Lund University, Lund, Sweden
| | - Sara Regner
- Section of Surgery, Department of Clinical Sciences, Malmö, Sweden
| | | |
Collapse
|
32
|
Zhou Y, Park SY, Su J, Bailey K, Ottosson-Laakso E, Shcherbina L, Oskolkov N, Zhang E, Thevenin T, Fadista J, Bennet H, Vikman P, Wierup N, Fex M, Rung J, Wollheim C, Nobrega M, Renström E, Groop L, Hansson O. TCF7L2 is a master regulator of insulin production and processing. Hum Mol Genet 2014; 23:6419-31. [PMID: 25015099 PMCID: PMC4240194 DOI: 10.1093/hmg/ddu359] [Citation(s) in RCA: 133] [Impact Index Per Article: 13.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022] Open
Abstract
Genome-wide association studies have revealed >60 loci associated with type 2 diabetes (T2D), but the underlying causal variants and functional mechanisms remain largely elusive. Although variants in TCF7L2 confer the strongest risk of T2D among common variants by presumed effects on islet function, the molecular mechanisms are not yet well understood. Using RNA-sequencing, we have identified a TCF7L2-regulated transcriptional network responsible for its effect on insulin secretion in rodent and human pancreatic islets. ISL1 is a primary target of TCF7L2 and regulates proinsulin production and processing via MAFA, PDX1, NKX6.1, PCSK1, PCSK2 and SLC30A8, thereby providing evidence for a coordinated regulation of insulin production and processing. The risk T-allele of rs7903146 was associated with increased TCF7L2 expression, and decreased insulin content and secretion. Using gene expression profiles of 66 human pancreatic islets donors’, we also show that the identified TCF7L2-ISL1 transcriptional network is regulated in a genotype-dependent manner. Taken together, these results demonstrate that not only synthesis of proinsulin is regulated by TCF7L2 but also processing and possibly clearance of proinsulin and insulin. These multiple targets in key pathways may explain why TCF7L2 has emerged as the gene showing one of the strongest associations with T2D.
Collapse
Affiliation(s)
- Yuedan Zhou
- Department of Clinical Sciences, CRC, Lund University, Malmö 20502, Sweden
| | | | - Jing Su
- European Bioinformatics Institute, Functional Genomics, Hinxton, Cambridge CB10 1SD, UK
| | - Kathleen Bailey
- Department of Human Genetics, University of Chicago, IL 60637, USA
| | | | - Liliya Shcherbina
- Department of Clinical Sciences, CRC, Lund University, Malmö 20502, Sweden
| | - Nikolay Oskolkov
- Department of Clinical Sciences, CRC, Lund University, Malmö 20502, Sweden
| | - Enming Zhang
- Department of Clinical Sciences, CRC, Lund University, Malmö 20502, Sweden
| | - Thomas Thevenin
- Department of Clinical Sciences, CRC, Lund University, Malmö 20502, Sweden
| | - João Fadista
- Department of Clinical Sciences, CRC, Lund University, Malmö 20502, Sweden
| | - Hedvig Bennet
- Department of Clinical Sciences, CRC, Lund University, Malmö 20502, Sweden
| | - Petter Vikman
- Department of Clinical Sciences, CRC, Lund University, Malmö 20502, Sweden
| | - Nils Wierup
- Department of Clinical Sciences, CRC, Lund University, Malmö 20502, Sweden
| | - Malin Fex
- Department of Clinical Sciences, CRC, Lund University, Malmö 20502, Sweden
| | - Johan Rung
- Department of Immunology, Genetics and Pathology, Rudbeck Laboratory, Uppsala University, Uppsala 75185, Sweden and
| | - Claes Wollheim
- Department of Clinical Sciences, CRC, Lund University, Malmö 20502, Sweden, Department of Cell Physiology and Metabolism, Université de Genève, University Medical Centre, 1 rue Michel-Servet, Geneva 4 1211, Switzerland
| | - Marcelo Nobrega
- Department of Human Genetics, University of Chicago, IL 60637, USA
| | - Erik Renström
- Department of Clinical Sciences, CRC, Lund University, Malmö 20502, Sweden
| | - Leif Groop
- Department of Clinical Sciences, CRC, Lund University, Malmö 20502, Sweden
| | - Ola Hansson
- Department of Clinical Sciences, CRC, Lund University, Malmö 20502, Sweden,
| |
Collapse
|
33
|
Zhang E, Kircher MF, Koch M, Eliasson L, Goldberg SN, Renström E. Dynamic magnetic fields remote-control apoptosis via nanoparticle rotation. ACS Nano 2014; 8:3192-201. [PMID: 24597847 PMCID: PMC4004315 DOI: 10.1021/nn406302j] [Citation(s) in RCA: 121] [Impact Index Per Article: 12.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/09/2013] [Accepted: 03/05/2014] [Indexed: 05/19/2023]
Abstract
The ability to control the movement of nanoparticles remotely and with high precision would have far-reaching implications in many areas of nanotechnology. We have designed a unique dynamic magnetic field (DMF) generator that can induce rotational movements of superparamagnetic iron oxide nanoparticles (SPIONs). We examined whether the rotational nanoparticle movement could be used for remote induction of cell death by injuring lysosomal membrane structures. We further hypothesized that the shear forces created by the generation of oscillatory torques (incomplete rotation) of SPIONs bound to lysosomal membranes would cause membrane permeabilization, lead to extravasation of lysosomal contents into the cytoplasm, and induce apoptosis. To this end, we covalently conjugated SPIONs with antibodies targeting the lysosomal protein marker LAMP1 (LAMP1-SPION). Remote activation of slow rotation of LAMP1-SPIONs significantly improved the efficacy of cellular internalization of the nanoparticles. LAMP1-SPIONs then preferentially accumulated along the membrane in lysosomes in both rat insulinoma tumor cells and human pancreatic beta cells due to binding of LAMP1-SPIONs to endogenous LAMP1. Further activation of torques by the LAMP1-SPIONs bound to lysosomes resulted in rapid decrease in size and number of lysosomes, attributable to tearing of the lysosomal membrane by the shear force of the rotationally activated LAMP1-SPIONs. This remote activation resulted in an increased expression of early and late apoptotic markers and impaired cell growth. Our findings suggest that DMF treatment of lysosome-targeted nanoparticles offers a noninvasive tool to induce apoptosis remotely and could serve as an important platform technology for a wide range of biomedical applications.
Collapse
Affiliation(s)
- Enming Zhang
- Department of Clinical Sciences Malmö, Lund University, Malmö 205 02, Sweden
- Address correspondence to ,
| | - Moritz F. Kircher
- Department of Radiology, Memorial Sloan-Kettering Cancer Center, New York, New York 10065, United States
- Department of Radiology, Weill Cornell Medical College, New York, New York 10038, United States
- Center for Molecular Imaging and Nanotechnology, Memorial Sloan-Kettering Cancer Center, New York, New York 10065, United States
| | - Martin Koch
- Stetter Elektronik, Seeheim-Jugenheim, Hessen 64342, Germany
| | - Lena Eliasson
- Department of Clinical Sciences Malmö, Lund University, Malmö 205 02, Sweden
| | - S. Nahum Goldberg
- Laboratory for Minimally Invasive Tumor Therapies, Department of Radiology, Beth Israel Deaconess Medical Center/Harvard Medical School, Boston, Massachusetts 02215, United States
- Division of Image-guided Therapy and Interventional Oncology, Department of Radiology, Hadassah Hebrew University Medical Center, Jerusalem, Israel
| | - Erik Renström
- Department of Clinical Sciences Malmö, Lund University, Malmö 205 02, Sweden
- Address correspondence to ,
| |
Collapse
|
34
|
Tuluc P, Mastrolia V, Drach M, Flucher SM, Renström E, Striessnig J, Flucher BE. Calcium Channel α2δ-1 Subunit Knockout Causes Diabetes Due to Impaired Insulin Release. Biophys J 2014. [DOI: 10.1016/j.bpj.2013.11.1902] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
35
|
Taneera J, Fadista J, Ahlqvist E, Zhang M, Wierup N, Renström E, Groop L. Expression profiling of cell cycle genes in human pancreatic islets with and without type 2 diabetes. Mol Cell Endocrinol 2013; 375:35-42. [PMID: 23707792 DOI: 10.1016/j.mce.2013.05.003] [Citation(s) in RCA: 39] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/07/2012] [Revised: 04/30/2013] [Accepted: 05/01/2013] [Indexed: 02/07/2023]
Abstract
Microarray gene expression data were used to analyze the expression pattern of cyclin, cyclin-dependent kinase (CDKs) and cyclin-dependent kinase inhibitor (CDKIs) genes from human pancreatic islets with and without type 2 diabetes (T2D). Of the cyclin genes, CCNI was the most expressed. Data obtained from microarray and qRT-PCR showed higher expression of CCND1 in diabetic islets. Among the CDKs, CDK4, CDK8 and CDK9 were highly expressed, while CDK1 was expressed at low level. High expression of CDK18 was observed in diabetic islets. Of the CDKIs, CDKN1A expression was higher in diabetic islets in both microarray and qRT-PCR. Expression of CDKN1A, CDKN2A, CCNI2, CDK3 and CDK16 was correlated with age. Finally, eight SNPs in these genes were associated with T2D in the DIAGRAM database. Our data provide a comprehensive expression pattern of cell cycle genes in human islets. More human studies are required to confirm and reproduce animal studies.
Collapse
Affiliation(s)
- Jalal Taneera
- Lund University Diabetes Center, Department of Clinical Sciences, Diabetes & Endocrinology, Skåne University Hospital, Lund University, Malmö 20502, Sweden.
| | | | | | | | | | | | | |
Collapse
|
36
|
Jonsson A, Ladenvall C, Ahluwalia TS, Kravic J, Krus U, Taneera J, Isomaa B, Tuomi T, Renström E, Groop L, Lyssenko V. Effects of common genetic variants associated with type 2 diabetes and glycemic traits on α- and β-cell function and insulin action in humans. Diabetes 2013; 62:2978-83. [PMID: 23557703 PMCID: PMC3717852 DOI: 10.2337/db12-1627] [Citation(s) in RCA: 72] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
Abstract
Although meta-analyses of genome-wide association studies have identified >60 single nucleotide polymorphisms (SNPs) associated with type 2 diabetes and/or glycemic traits, there is little information on whether these variants also affect α-cell function. The aim of the current study was to evaluate the effects of glycemia-associated genetic loci on islet function in vivo and in vitro. We studied 43 SNPs in 4,654 normoglycemic participants from the Finnish population-based Prevalence, Prediction, and Prevention of Diabetes-Botnia (PPP-Botnia) Study. Islet function was assessed, in vivo, by measuring insulin and glucagon concentrations during oral glucose tolerance test, and, in vitro, by measuring glucose-stimulated insulin and glucagon secretion from human pancreatic islets. Carriers of risk variants in BCL11A, HHEX, ZBED3, HNF1A, IGF1, and NOTCH2 showed elevated whereas those in CRY2, IGF2BP2, TSPAN8, and KCNJ11 showed decreased fasting and/or 2-h glucagon concentrations in vivo. Variants in BCL11A, TSPAN8, and NOTCH2 affected glucagon secretion both in vivo and in vitro. The MTNR1B variant was a clear outlier in the relationship analysis between insulin secretion and action, as well as between insulin, glucose, and glucagon. Many of the genetic variants shown to be associated with type 2 diabetes or glycemic traits also exert pleiotropic in vivo and in vitro effects on islet function.
Collapse
Affiliation(s)
- Anna Jonsson
- Department of Clinical Sciences, Diabetes and Endocrinology, Lund University Diabetes Centre, Lund University, Malmö, Sweden.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
37
|
Buda P, Reinbothe T, Nagaraj V, Mahdi T, Luan C, Tang Y, Axelsson AS, Li D, Rosengren AH, Renström E, Zhang E. Eukaryotic translation initiation factor 3 subunit e controls intracellular calcium homeostasis by regulation of cav1.2 surface expression. PLoS One 2013; 8:e64462. [PMID: 23737983 PMCID: PMC3667822 DOI: 10.1371/journal.pone.0064462] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/11/2012] [Accepted: 04/15/2013] [Indexed: 01/09/2023] Open
Abstract
Inappropriate surface expression of voltage-gated Ca2+channels (CaV) in pancreatic ß-cells may contribute to the development of type 2 diabetes. First, failure to increase intracellular Ca2+ concentrations at the sites of exocytosis impedes insulin release. Furthermore, excessive Ca2+ influx may trigger cytotoxic effects. The regulation of surface expression of CaV channels in the pancreatic β-cells remains unknown. Here, we used real-time 3D confocal and TIRFM imaging, immunocytochemistry, cellular fractionation, immunoprecipitation and electrophysiology to study trafficking of L-type CaV1.2 channels upon β-cell stimulation. We found decreased surface expression of CaV1.2 and a corresponding reduction in L-type whole-cell Ca2+ currents in insulin-secreting INS-1 832/13 cells upon protracted (15–30 min) stimulation. This internalization occurs by clathrin-dependent endocytosis and could be prevented by microtubule or dynamin inhibitors. eIF3e (Eukaryotic translation initiation factor 3 subunit E) is part of the protein translation initiation complex, but its effect on translation are modest and effects in ion channel trafficking have been suggested. The factor interacted with CaV1.2 and regulated CaV1.2 traffic bidirectionally. eIF3e silencing impaired CaV1.2 internalization, which resulted in an increased intracellular Ca2+ load upon stimulation. These findings provide a mechanism for regulation of L-type CaV channel surface expression with consequences for β-cell calcium homeostasis, which will affect pancreatic β-cell function and insulin production.
Collapse
Affiliation(s)
- Pawel Buda
- Lund University Diabetes Center, Malmö, Sweden
| | | | | | - Taman Mahdi
- Lund University Diabetes Center, Malmö, Sweden
| | - Cheng Luan
- Lund University Diabetes Center, Malmö, Sweden
| | - Yunzhao Tang
- Lund University Diabetes Center, Malmö, Sweden
- Key Lab of Hormones and Development, Ministry of Health, and Metabolic Diseases Hospital, Tianjin Medical University, Tianjin, China
| | | | - Daiqing Li
- Key Lab of Hormones and Development, Ministry of Health, and Metabolic Diseases Hospital, Tianjin Medical University, Tianjin, China
| | | | - Erik Renström
- Lund University Diabetes Center, Malmö, Sweden
- * E-mail: (ER); (EZ)
| | - Enming Zhang
- Lund University Diabetes Center, Malmö, Sweden
- * E-mail: (ER); (EZ)
| |
Collapse
|
38
|
Reinbothe TM, Alkayyali S, Ahlqvist E, Tuomi T, Isomaa B, Lyssenko V, Renström E. The human L-type calcium channel Cav1.3 regulates insulin release and polymorphisms in CACNA1D associate with type 2 diabetes. Diabetologia 2013; 56:340-9. [PMID: 23229155 DOI: 10.1007/s00125-012-2758-z] [Citation(s) in RCA: 63] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/25/2012] [Accepted: 10/02/2012] [Indexed: 01/08/2023]
Abstract
AIMS/HYPOTHESIS Voltage-gated calcium channels of the L-type have been shown to be essential for rodent pancreatic beta cell function, but data about their presence and regulation in humans are incomplete. We therefore sought to elucidate which L-type channel isoform is functionally important and its association with inherited diabetes-related phenotypes. METHODS Beta cells of human islets from cadaver donors were enriched using FACS to study the expression of the genes encoding voltage-gated calcium channel (Cav)1.2 and Cav1.3 by absolute quantitative PCR in whole human and rat islets, as well as in clonal cells. Single-cell exocytosis was monitored as increases in cell capacitance after treatment with small interfering (si)RNA against CACNA1D (which encodes Cav1.3). Three single nucleotide polymorphisms (SNPs) were genotyped in 8,987 non-diabetic and 2,830 type 2 diabetic individuals from Finland and Sweden and analysed for associations with type 2 diabetes and insulin phenotypes. RESULTS In FACS-enriched human beta cells, CACNA1D mRNA expression exceeded that of CACNA1C (which encodes Cav1.2) by approximately 60-fold and was decreased in islets from type 2 diabetes patients. The latter coincided with diminished secretion of insulin in vitro. CACNA1D siRNA reduced glucose-stimulated insulin release in INS-1 832/13 cells and exocytosis in human beta cells. Phenotype/genotype associations of three SNPs in the CACNA1D gene revealed an association between the C allele of the SNP rs312480 and reduced mRNA expression, as well as decreased insulin secretion in vivo, whereas both rs312486/G and rs9841978/G were associated with type 2 diabetes. CONCLUSION/INTERPRETATION We conclude that the L-type calcium channel Cav1.3 is important in human glucose-induced insulin secretion, and common variants in CACNA1D might contribute to type 2 diabetes.
Collapse
Affiliation(s)
- T M Reinbothe
- Department of Clinical Sciences, Islet Pathophysiology, Lund University Diabetes Centre, Jan Waldenströms gata 35, , Malmö, Sweden.
| | | | | | | | | | | | | |
Collapse
|
39
|
Mahdi T, Hänzelmann S, Salehi A, Muhammed SJ, Reinbothe TM, Tang Y, Axelsson AS, Zhou Y, Jing X, Almgren P, Krus U, Taneera J, Blom AM, Lyssenko V, Esguerra JLS, Hansson O, Eliasson L, Derry J, Zhang E, Wollheim CB, Groop L, Renström E, Rosengren AH. Secreted frizzled-related protein 4 reduces insulin secretion and is overexpressed in type 2 diabetes. Cell Metab 2012; 16:625-33. [PMID: 23140642 DOI: 10.1016/j.cmet.2012.10.009] [Citation(s) in RCA: 133] [Impact Index Per Article: 11.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/06/2012] [Revised: 09/10/2012] [Accepted: 10/22/2012] [Indexed: 12/12/2022]
Abstract
A plethora of candidate genes have been identified for complex polygenic disorders, but the underlying disease mechanisms remain largely unknown. We explored the pathophysiology of type 2 diabetes (T2D) by analyzing global gene expression in human pancreatic islets. A group of coexpressed genes (module), enriched for interleukin-1-related genes, was associated with T2D and reduced insulin secretion. One of the module genes that was highly overexpressed in islets from T2D patients is SFRP4, which encodes secreted frizzled-related protein 4. SFRP4 expression correlated with inflammatory markers, and its release from islets was stimulated by interleukin-1β. Elevated systemic SFRP4 caused reduced glucose tolerance through decreased islet expression of Ca(2+) channels and suppressed insulin exocytosis. SFRP4 thus provides a link between islet inflammation and impaired insulin secretion. Moreover, the protein was increased in serum from T2D patients several years before the diagnosis, suggesting that SFRP4 could be a potential biomarker for islet dysfunction in T2D.
Collapse
Affiliation(s)
- Taman Mahdi
- Lund University Diabetes Centre, Lund University, 20502 Malmö, Sweden
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
40
|
Abstract
Common genetic variations in the gene encoding transcription factor 7-like 2 (TCF7L2) reveal the strongest association with type 2-diabetes known to date. These lead to impaired insulin production and output, but the mechanisms of disease remain incompletely known. In this issue of Diabetologia, two publications provide new insights into TCF7L2-dependent diabetes.
Collapse
Affiliation(s)
- E Renström
- Lund University Diabetes Center, Inga-Marie Nilssons gata 53 floor 3, 205 02, Malmö, Sweden.
| |
Collapse
|
41
|
Hindy G, Sonestedt E, Ericson U, Jing XJ, Zhou Y, Hansson O, Renström E, Wirfält E, Orho-Melander M. Role of TCF7L2 risk variant and dietary fibre intake on incident type 2 diabetes. Diabetologia 2012; 55:2646-2654. [PMID: 22782288 PMCID: PMC3433658 DOI: 10.1007/s00125-012-2634-x] [Citation(s) in RCA: 54] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/20/2012] [Accepted: 06/06/2012] [Indexed: 11/30/2022]
Abstract
AIMS/HYPOTHESIS The T allele of transcription factor 7-like 2 gene variant, TCF7L2 rs7903146, increases the risk of type 2 diabetes by 40-50%. As TCF7L2 rs7903146 has been associated with diminished incretin effect we investigated whether interaction between dietary intake of carbohydrate, fat, protein or fibre and this variant affects the risk of type 2 diabetes. METHODS A cohort of 24,799 non-diabetic individuals from the Malmö Diet and Cancer Study (MDCS), with dietary data obtained by a modified diet history method, were followed up for 12 years, with 1,649 recordings of incident type 2 diabetes made. Risk of type 2 diabetes in strata of diet quintiles was analysed prospectively adjusting for potential confounders. Cross-sectional analyses were performed on baseline fasting glucose and HbA(1c) levels in a subset of 5,216 randomly selected individuals from the MDCS. RESULTS The elevated risk of type 2 diabetes with rs7903146 (OR 1.44, 95% CI 1.33, 1.56, p = 4.6 × 10(-19)) increased with higher intake of dietary fibre (OR 1.24, 95% CI 1.04, 1.47 to OR 1.56, 95% CI 1.31, 1.86 from the lowest to highest quintile; p (interaction) = 0.049). High intake of dietary fibre was inversely associated with diabetes incidence only among CC genotype carriers (OR 0.74, 95% CI 0.58, 0.94 per quintile, p = 0.025). The T allele was associated with 0.027% elevated HbA(1c) (p = 0.02) and this effect increased with higher intake of fibre (from -0.021% to 0.079% for the lowest to the highest quintile, p (interaction) = 0.02). Each quintile of higher fibre intake was associated with lower HbA(1c) levels among CC and CT but not among TT genotype carriers (-0.036%, p = 6.5 × 10(-7); -0.023%, p = 0.009; and 0.012%, p = 0.52, respectively). CONCLUSIONS/INTERPRETATION Our study suggests that dietary fibre intake may modify the association between TCF7L2 rs7903146 and incidence of type 2 diabetes, and that higher fibre intake may associate with protection from type 2 diabetes only among non-risk allele carriers.
Collapse
Affiliation(s)
- G Hindy
- Department of Clinical Sciences in Malmö, Lund University, Clinical Research Center, Malmö, Sweden
| | - E Sonestedt
- Department of Clinical Sciences in Malmö, Lund University, Clinical Research Center, Malmö, Sweden
| | - U Ericson
- Department of Clinical Sciences in Malmö, Lund University, Clinical Research Center, Malmö, Sweden
| | - X-J Jing
- Department of Clinical Sciences in Malmö, Lund University, Clinical Research Center, Malmö, Sweden
| | - Y Zhou
- Department of Clinical Sciences in Malmö, Lund University, Clinical Research Center, Malmö, Sweden
| | - O Hansson
- Department of Clinical Sciences in Malmö, Lund University, Clinical Research Center, Malmö, Sweden
| | - E Renström
- Department of Clinical Sciences in Malmö, Lund University, Clinical Research Center, Malmö, Sweden
| | - E Wirfält
- Department of Clinical Sciences in Malmö, Lund University, Clinical Research Center, Malmö, Sweden
| | - M Orho-Melander
- Department of Clinical Sciences in Malmö, Lund University, Clinical Research Center, Malmö, Sweden.
- Diabetes and Cardiovascular Disease, Genetic Epidemiology, Department of Clinical Sciences, Lund University Diabetes Centre, Lund University, Clinical Research Centre 91:12, Jan Waldenströms gata 35, 20502, Malmö, Sweden.
| |
Collapse
|
42
|
Taneera J, Lang S, Sharma A, Fadista J, Zhou Y, Ahlqvist E, Jonsson A, Lyssenko V, Vikman P, Hansson O, Parikh H, Korsgren O, Soni A, Krus U, Zhang E, Jing XJ, Esguerra JLS, Wollheim CB, Salehi A, Rosengren A, Renström E, Groop L. A systems genetics approach identifies genes and pathways for type 2 diabetes in human islets. Cell Metab 2012; 16:122-34. [PMID: 22768844 DOI: 10.1016/j.cmet.2012.06.006] [Citation(s) in RCA: 271] [Impact Index Per Article: 22.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/30/2011] [Revised: 02/05/2012] [Accepted: 06/18/2012] [Indexed: 12/13/2022]
Abstract
Close to 50 genetic loci have been associated with type 2 diabetes (T2D), but they explain only 15% of the heritability. In an attempt to identify additional T2D genes, we analyzed global gene expression in human islets from 63 donors. Using 48 genes located near T2D risk variants, we identified gene coexpression and protein-protein interaction networks that were strongly associated with islet insulin secretion and HbA(1c). We integrated our data to form a rank list of putative T2D genes, of which CHL1, LRFN2, RASGRP1, and PPM1K were validated in INS-1 cells to influence insulin secretion, whereas GPR120 affected apoptosis in islets. Expression variation of the top 20 genes explained 24% of the variance in HbA(1c) with no claim of the direction. The data present a global map of genes associated with islet dysfunction and demonstrate the value of systems genetics for the identification of genes potentially involved in T2D.
Collapse
Affiliation(s)
- Jalal Taneera
- Lund University Diabetes Center, Department of Clinical Sciences, Diabetes and Endocrinology, Skåne University Hospital Malmö, Lund University, Malmö 20502, Sweden.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
43
|
Rosengren AH, Braun M, Mahdi T, Andersson SA, Travers ME, Shigeto M, Zhang E, Almgren P, Ladenvall C, Axelsson AS, Edlund A, Pedersen MG, Jonsson A, Ramracheya R, Tang Y, Walker JN, Barrett A, Johnson PR, Lyssenko V, McCarthy MI, Groop L, Salehi A, Gloyn AL, Renström E, Rorsman P, Eliasson L. Reduced insulin exocytosis in human pancreatic β-cells with gene variants linked to type 2 diabetes. Diabetes 2012; 61:1726-33. [PMID: 22492527 PMCID: PMC3379663 DOI: 10.2337/db11-1516] [Citation(s) in RCA: 179] [Impact Index Per Article: 14.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Abstract
The majority of genetic risk variants for type 2 diabetes (T2D) affect insulin secretion, but the mechanisms through which they influence pancreatic islet function remain largely unknown. We functionally characterized human islets to determine secretory, biophysical, and ultrastructural features in relation to genetic risk profiles in diabetic and nondiabetic donors. Islets from donors with T2D exhibited impaired insulin secretion, which was more pronounced in lean than obese diabetic donors. We assessed the impact of 14 disease susceptibility variants on measures of glucose sensing, exocytosis, and structure. Variants near TCF7L2 and ADRA2A were associated with reduced glucose-induced insulin secretion, whereas susceptibility variants near ADRA2A, KCNJ11, KCNQ1, and TCF7L2 were associated with reduced depolarization-evoked insulin exocytosis. KCNQ1, ADRA2A, KCNJ11, HHEX/IDE, and SLC2A2 variants affected granule docking. We combined our results to create a novel genetic risk score for β-cell dysfunction that includes aberrant granule docking, decreased Ca(2+) sensitivity of exocytosis, and reduced insulin release. Individuals with a high risk score displayed an impaired response to intravenous glucose and deteriorating insulin secretion over time. Our results underscore the importance of defects in β-cell exocytosis in T2D and demonstrate the potential of cellular phenotypic characterization in the elucidation of complex genetic disorders.
Collapse
Affiliation(s)
- Anders H. Rosengren
- Lund University Diabetes Centre, Department of Clinical Sciences Malmo, Lund University, Malmo, Sweden
- Corresponding author: Anders H. Rosengren, , or Lena Eliasson,
| | - Matthias Braun
- Oxford Centre for Diabetes, Endocrinology, and Metabolism, University of Oxford, Churchill Hospital, Oxford, U.K
- Alberta Diabetes Institute, University of Alberta, Edmonton, Alberta, Canada
| | - Taman Mahdi
- Lund University Diabetes Centre, Department of Clinical Sciences Malmo, Lund University, Malmo, Sweden
| | - Sofia A. Andersson
- Lund University Diabetes Centre, Department of Clinical Sciences Malmo, Lund University, Malmo, Sweden
| | - Mary E. Travers
- Oxford Centre for Diabetes, Endocrinology, and Metabolism, University of Oxford, Churchill Hospital, Oxford, U.K
| | - Makoto Shigeto
- Oxford Centre for Diabetes, Endocrinology, and Metabolism, University of Oxford, Churchill Hospital, Oxford, U.K
| | - Enming Zhang
- Lund University Diabetes Centre, Department of Clinical Sciences Malmo, Lund University, Malmo, Sweden
| | - Peter Almgren
- Lund University Diabetes Centre, Department of Clinical Sciences Malmo, Lund University, Malmo, Sweden
| | - Claes Ladenvall
- Lund University Diabetes Centre, Department of Clinical Sciences Malmo, Lund University, Malmo, Sweden
| | - Annika S. Axelsson
- Lund University Diabetes Centre, Department of Clinical Sciences Malmo, Lund University, Malmo, Sweden
| | - Anna Edlund
- Lund University Diabetes Centre, Department of Clinical Sciences Malmo, Lund University, Malmo, Sweden
| | - Morten Gram Pedersen
- Lund University Diabetes Centre, Department of Clinical Sciences Malmo, Lund University, Malmo, Sweden
| | - Anna Jonsson
- Lund University Diabetes Centre, Department of Clinical Sciences Malmo, Lund University, Malmo, Sweden
| | - Reshma Ramracheya
- Oxford Centre for Diabetes, Endocrinology, and Metabolism, University of Oxford, Churchill Hospital, Oxford, U.K
| | - Yunzhao Tang
- Lund University Diabetes Centre, Department of Clinical Sciences Malmo, Lund University, Malmo, Sweden
- Key Laboratory of Hormones and Development, Ministry of Health, China, Metabolic Diseases Hospital, Tianjin Medical University, Tianjin, China
| | - Jonathan N. Walker
- Oxford Centre for Diabetes, Endocrinology, and Metabolism, University of Oxford, Churchill Hospital, Oxford, U.K
- Oxford National Institute for Health Research Biomedical Research Centre, Churchill Hospital, Oxford, U.K
| | - Amy Barrett
- Oxford Centre for Diabetes, Endocrinology, and Metabolism, University of Oxford, Churchill Hospital, Oxford, U.K
| | - Paul R.V. Johnson
- Oxford Centre for Diabetes, Endocrinology, and Metabolism, University of Oxford, Churchill Hospital, Oxford, U.K
- Oxford National Institute for Health Research Biomedical Research Centre, Churchill Hospital, Oxford, U.K
- Nuffield Department of Surgery, University of Oxford, Oxford, U.K
| | - Valeriya Lyssenko
- Lund University Diabetes Centre, Department of Clinical Sciences Malmo, Lund University, Malmo, Sweden
| | - Mark I. McCarthy
- Oxford Centre for Diabetes, Endocrinology, and Metabolism, University of Oxford, Churchill Hospital, Oxford, U.K
- Oxford National Institute for Health Research Biomedical Research Centre, Churchill Hospital, Oxford, U.K
- Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, U.K
| | - Leif Groop
- Lund University Diabetes Centre, Department of Clinical Sciences Malmo, Lund University, Malmo, Sweden
| | - Albert Salehi
- Lund University Diabetes Centre, Department of Clinical Sciences Malmo, Lund University, Malmo, Sweden
| | - Anna L. Gloyn
- Oxford Centre for Diabetes, Endocrinology, and Metabolism, University of Oxford, Churchill Hospital, Oxford, U.K
- Oxford National Institute for Health Research Biomedical Research Centre, Churchill Hospital, Oxford, U.K
| | - Erik Renström
- Lund University Diabetes Centre, Department of Clinical Sciences Malmo, Lund University, Malmo, Sweden
| | - Patrik Rorsman
- Oxford Centre for Diabetes, Endocrinology, and Metabolism, University of Oxford, Churchill Hospital, Oxford, U.K
- Alberta Diabetes Institute, University of Alberta, Edmonton, Alberta, Canada
- Oxford National Institute for Health Research Biomedical Research Centre, Churchill Hospital, Oxford, U.K
| | - Lena Eliasson
- Lund University Diabetes Centre, Department of Clinical Sciences Malmo, Lund University, Malmo, Sweden
- Corresponding author: Anders H. Rosengren, , or Lena Eliasson,
| |
Collapse
|
44
|
Taneera J, Jin Z, Jin Y, Muhammed SJ, Zhang E, Lang S, Salehi A, Korsgren O, Renström E, Groop L, Birnir B. γ-Aminobutyric acid (GABA) signalling in human pancreatic islets is altered in type 2 diabetes. Diabetologia 2012; 55:1985-94. [PMID: 22538358 PMCID: PMC3369140 DOI: 10.1007/s00125-012-2548-7] [Citation(s) in RCA: 72] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/12/2011] [Accepted: 03/07/2012] [Indexed: 12/31/2022]
Abstract
AIMS/HYPOTHESIS γ-Aminobutyric acid (GABA) is a signalling molecule in the interstitial space in pancreatic islets. We examined the expression and function of the GABA signalling system components in human pancreatic islets from normoglycaemic and type 2 diabetic individuals. METHODS Expression of GABA signalling system components was studied by microarray, quantitative PCR analysis, immunohistochemistry and patch-clamp experiments on cells in intact islets. Hormone release was measured from intact islets. RESULTS The GABA signalling system was compromised in islets from type 2 diabetic individuals, where the expression of the genes encoding the α1, α2, β2 and β3 GABA(A) channel subunits was downregulated. GABA originating within the islets evoked tonic currents in the cells. The currents were enhanced by pentobarbital and inhibited by the GABA(A) receptor antagonist, SR95531. The effects of SR95531 on hormone release revealed that activation of GABA(A) channels (GABA(A) receptors) decreased both insulin and glucagon secretion. The GABA(B) receptor antagonist, CPG55845, increased insulin release in islets (16.7 mmol/l glucose) from normoglycaemic and type 2 diabetic individuals. CONCLUSIONS/INTERPRETATION Interstitial GABA activates GABA(A) channels and GABA(B) receptors and effectively modulates hormone release in islets from type 2 diabetic and normoglycaemic individuals.
Collapse
Affiliation(s)
- J. Taneera
- Lund University Diabetes Center, Department of Clinical Sciences, Diabetes & Endocrinology, University Hospital Malmö, Lund University, Malmö, Sweden
| | - Z. Jin
- Department of Neuroscience, Uppsala University, Box 593, 75124 Uppsala, Sweden
| | - Y. Jin
- Department of Neuroscience, Uppsala University, Box 593, 75124 Uppsala, Sweden
| | - S. J. Muhammed
- Department of Clinical Sciences, Islet Cell physiology, University Hospital Malmö, Lund University, Malmö, Sweden
| | - E. Zhang
- Department of Clinical Sciences, Islet Pathophysiology, University Hospital Malmö, Lund University, Malmö, 20502 Sweden
| | - S. Lang
- Department of Neuroscience, Uppsala University, Box 593, 75124 Uppsala, Sweden
- Lund University Diabetes Center, Department of Clinical Sciences, Diabetes & Endocrinology, University Hospital Malmö, Lund University, Malmö, Sweden
| | - A. Salehi
- Department of Clinical Sciences, Islet Cell physiology, University Hospital Malmö, Lund University, Malmö, Sweden
| | - O. Korsgren
- Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, 75185 Sweden
| | - E. Renström
- Department of Clinical Sciences, Islet Pathophysiology, University Hospital Malmö, Lund University, Malmö, 20502 Sweden
| | - L. Groop
- Lund University Diabetes Center, Department of Clinical Sciences, Diabetes & Endocrinology, University Hospital Malmö, Lund University, Malmö, Sweden
| | - B. Birnir
- Department of Neuroscience, Uppsala University, Box 593, 75124 Uppsala, Sweden
| |
Collapse
|
45
|
Yang BT, Dayeh TA, Volkov PA, Kirkpatrick CL, Malmgren S, Jing X, Renström E, Wollheim CB, Nitert MD, Ling C. Increased DNA methylation and decreased expression of PDX-1 in pancreatic islets from patients with type 2 diabetes. Mol Endocrinol 2012; 26:1203-12. [PMID: 22570331 DOI: 10.1210/me.2012-1004] [Citation(s) in RCA: 196] [Impact Index Per Article: 16.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022] Open
Abstract
Mutations in pancreatic duodenal homeobox 1 (PDX-1) can cause a monogenic form of diabetes (maturity onset diabetes of the young 4) in humans, and silencing Pdx-1 in pancreatic β-cells of mice causes diabetes. However, it is not established whether epigenetic alterations of PDX-1 influence type 2 diabetes (T2D) in humans. Here we analyzed mRNA expression and DNA methylation of PDX-1 in human pancreatic islets from 55 nondiabetic donors and nine patients with T2D. We further studied epigenetic regulation of PDX-1 in clonal β-cells. PDX-1 expression was decreased in pancreatic islets from patients with T2D compared with nondiabetic donors (P = 0.0002) and correlated positively with insulin expression (rho = 0.59, P = 0.000001) and glucose-stimulated insulin secretion (rho = 0.41, P = 0.005) in the human islets. Ten CpG sites in the distal PDX-1 promoter and enhancer regions exhibited significantly increased DNA methylation in islets from patients with T2D compared with nondiabetic donors. DNA methylation of PDX-1 correlated negatively with its gene expression in the human islets (rho = -0.64, P = 0.0000029). Moreover, methylation of the human PDX-1 promoter and enhancer regions suppressed reporter gene expression in clonal β-cells (P = 0.04). Our data further indicate that hyperglycemia decreases gene expression and increases DNA methylation of PDX-1 because glycosylated hemoglobin (HbA1c) correlates negatively with mRNA expression (rho = -0.50, P = 0.0004) and positively with DNA methylation (rho = 0.54, P = 0.00024) of PDX-1 in the human islets. Furthermore, while Pdx-1 expression decreased, Pdx-1 methylation and Dnmt1 expression increased in clonal β-cells exposed to high glucose. Overall, epigenetic modifications of PDX-1 may play a role in the development of T2D, given that pancreatic islets from patients with T2D and β-cells exposed to hyperglycemia exhibited increased DNA methylation and decreased expression of PDX-1. The expression levels of PDX-1 were further associated with insulin secretion in the human islets.
Collapse
Affiliation(s)
- Beatrice T Yang
- Department of Clinical Sciences, Unit of Epigenetics and Diabetes, Lund University Diabetes Centre, Scania University Hospital, 205 02 Malmoe, Sweden
| | | | | | | | | | | | | | | | | | | |
Collapse
|
46
|
Paul G, Özen I, Christophersen NS, Reinbothe T, Bengzon J, Visse E, Jansson K, Dannaeus K, Henriques-Oliveira C, Roybon L, Anisimov SV, Renström E, Svensson M, Haegerstrand A, Brundin P. The adult human brain harbors multipotent perivascular mesenchymal stem cells. PLoS One 2012; 7:e35577. [PMID: 22523602 PMCID: PMC3327668 DOI: 10.1371/journal.pone.0035577] [Citation(s) in RCA: 154] [Impact Index Per Article: 12.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/21/2011] [Accepted: 03/20/2012] [Indexed: 12/16/2022] Open
Abstract
Blood vessels and adjacent cells form perivascular stem cell niches in adult tissues. In this perivascular niche, a stem cell with mesenchymal characteristics was recently identified in some adult somatic tissues. These cells are pericytes that line the microvasculature, express mesenchymal markers and differentiate into mesodermal lineages but might even have the capacity to generate tissue-specific cell types. Here, we isolated, purified and characterized a previously unrecognized progenitor population from two different regions in the adult human brain, the ventricular wall and the neocortex. We show that these cells co-express markers for mesenchymal stem cells and pericytes in vivo and in vitro, but do not express glial, neuronal progenitor, hematopoietic, endothelial or microglial markers in their native state. Furthermore, we demonstrate at a clonal level that these progenitors have true multilineage potential towards both, the mesodermal and neuroectodermal phenotype. They can be epigenetically induced in vitro into adipocytes, chondroblasts and osteoblasts but also into glial cells and immature neurons. This progenitor population exhibits long-term proliferation, karyotype stability and retention of phenotype and multipotency following extensive propagation. Thus, we provide evidence that the vascular niche in the adult human brain harbors a novel progenitor with multilineage capacity that appears to represent mesenchymal stem cells and is different from any previously described human neural stem cell. Future studies will elucidate whether these cells may play a role for disease or may represent a reservoir that can be exploited in efforts to repair the diseased human brain.
Collapse
Affiliation(s)
- Gesine Paul
- Neuronal Survival Unit, Department of Experimental Medical Science, Wallenberg Neuroscience Center, Lund University, Lund, Sweden.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
47
|
King BC, Nowakowska J, Karsten CM, Köhl J, Renström E, Blom AM. Truncated and full-length thioredoxin-1 have opposing activating and inhibitory properties for human complement with relevance to endothelial surfaces. J Immunol 2012; 188:4103-12. [PMID: 22430737 DOI: 10.4049/jimmunol.1101295] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
Thioredoxin (Trx)-1 is a small, ubiquitously expressed redox-active protein with known important cytosolic functions. However, Trx1 is also upregulated in response to various stress stimuli, is found both at the cell surface and secreted into plasma, and has known anti-inflammatory and antiapoptotic properties. Previous animal studies have demonstrated that exogenous Trx1 delivery can have therapeutic effects in a number of disease models and have implicated an interaction of Trx1 with the complement system. We found that Trx1 is expressed in a redox-active form at the surface of HUVEC and acts as an inhibitor of complement deposition in a manner dependent on its Cys-Gly-Pro-Cys active site. Inhibition occurred at the point of the C5 convertase of complement, regulating production of C5a and the membrane attack complex. A truncated form of Trx1 also exists in vivo, Trx80, which has separate nonoverlapping functions compared with the full-length Trx1. We found that Trx80 activates the classical and alternative pathways of complement activation, leading to C5a production, but the inflammatory potential of this was also limited by the binding of inhibitors C4b-binding protein and factor H. This study adds a further role to the known anti-inflammatory properties of Trx1 and highlights the difference in function between the full-length and truncated forms.
Collapse
Affiliation(s)
- Ben C King
- Section of Medical Protein Chemistry, Department of Laboratory Medicine, Lund University, S-205 02 Malmö, Sweden
| | | | | | | | | | | |
Collapse
|
48
|
Sjölander J, Westermark GT, Renström E, Blom AM. Islet amyloid polypeptide triggers limited complement activation and binds complement inhibitor C4b-binding protein, which enhances fibril formation. J Biol Chem 2012; 287:10824-33. [PMID: 22334700 DOI: 10.1074/jbc.m111.244285] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022] Open
Abstract
Islet amyloid polypeptide (IAPP) is synthesized in pancreatic β-cells and co-secreted with insulin. Aggregation and formation of IAPP-amyloid play a critical role in β-cell death in type 2 diabetic patients. Because Aβ-fibrils in Alzheimer disease activate the complement system, we have here investigated specific interactions between IAPP and complement factors. IAPP fibrils triggered limited activation of complement in vitro, involving both the classical and the alternative pathways. Direct binding assays confirmed that IAPP fibrils interact with globular head domains of complement initiator C1q. Furthermore, IAPP also bound complement inhibitors factor H and C4b-binding protein (C4BP). Recombinant C4BP mutants were used to show that complement control protein (CCP) domains 8 and 2 of the α-chain were responsible for the strong, hydrophobic binding of C4BP to IAPP. Immunostaining of pancreatic sections from type 2 diabetic patients revealed the presence of complement factors in the islets and varying degree of co-localization between IAPP fibrils and C1q, C3d, as well as C4BP and factor H but not membrane attack complex. Furthermore, C4BP enhanced formation of IAPP fibrils in vitro. We conclude that C4BP binds to IAPP thereby limiting complement activation and may be enhancing formation of IAPP fibrils from cytotoxic oligomers.
Collapse
Affiliation(s)
- Jonatan Sjölander
- Department of Laboratory Medicine, Lund University, Wallenberg Laboratory, Skåne University Hospital, S-20502 Malmö, Sweden
| | | | | | | |
Collapse
|
49
|
Zhou Y, Zhang E, Berggreen C, Jing X, Osmark P, Lang S, Cilio CM, Göransson O, Groop L, Renström E, Hansson O. Survival of pancreatic beta cells is partly controlled by a TCF7L2-p53-p53INP1-dependent pathway. Hum Mol Genet 2011; 21:196-207. [PMID: 21965303 DOI: 10.1093/hmg/ddr454] [Citation(s) in RCA: 50] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022] Open
Abstract
The transcription factor T-cell factor 7-like 2 (TCF7L2) confers type 2 diabetes risk mainly through impaired insulin secretion, perturbed incretin effect and reduced beta-cell survival. The aim of this study was to identify the molecular mechanism through which TCF7L2 influences beta-cell survival. TCF7L2 target genes in INS-1 cells were identified using Chromatin Immunoprecipitation. Validation of targets was obtained by: siRNA silencing, real-time quantitative polymerase chain reaction, electrophoretic mobility shift assay, luciferase reporter assays and western blot. Apoptosis rate was measured by DNA degradation and caspase-3 content. Islet viability was estimated by measuring metabolic rate. TCF7L2 binds to 3646 gene promoters in INS-1 cells in high or low glucose, including Tp53, Pten, Uggt1, Adamts9 and Fto. SiRNA-mediated reduction in TCF7L2 activity resulted in increased apoptosis and increased expression of Tp53, which resulted in elevated p53 protein activity and an increased expression of the p53 target gene Tp53inp1 (encoding p53-induced-nuclear-protein 1). Reversing the increase in p53INP1 protein expression, seen after Tcf7l2 silencing, protected INS-1 cells from Tcf7l2 depletion-induced apoptosis. This result was replicated in primary rat islets. The risk T-allele of rs7903146 is associated with increased TCF7L2 mRNA expression and transcriptional activity. On the other hand, in vitro silencing of TCF7L2 lead to increased apoptosis. One possibility is that the risk T-allele increases expression of an inhibitory TCF7L2 isoform with lower transcriptional activity. These results identify the p53-p53INP1 pathway as a molecular mechanism through which TCF7L2 may affect beta-cell survival and established a molecular link between Tcf7l2 and two type 2 diabetes-associated genes, Tp53inp1 and Adamts9.
Collapse
Affiliation(s)
- Yuedan Zhou
- Department of Clinical Sciences, CRC, Lund University, Malmö 20502, Sweden.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
50
|
Zhang E, Renström E, Kircher M, Koch M. Alternating Magnetic Fields Trigger Apoptosis by Destruction of Lysosomes with LAMP1-Targeted Nanoparticles. Biophys J 2011. [DOI: 10.1016/j.bpj.2010.12.2768] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|